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“A STUDY ON RED BLOOD CELL COUNT, 
DISTRIBUTION WIDTH AND NEUTROPHIL/ 
LYMPHOCYTE RATIO AS MARKERS OF VASCULAR 
INFLAMMATION IN THE EARLY DETECTION OF 
NON PROLIFERATIVE DIABETIC RETINOPATHY” 
 
ABSTRACT 
PRIMARY OBJECTIVE 
To study the correlation between RDW, RBC Count and 
Neutrophil/ Lymphoctye Ratio in the early detection of Diabetic 
Retinopathy. 
METHODOLOGY 
About 100 Type-II Diabetic patients with / without visual 
symptoms attending Ophthalmology and diabetology OPDs after 
satisfying the Inclusion/ Exclusion Criteria will be included in the 
study. All patients will be subjected to symptom analysis, clinical 
examination and laboratory investigation. Final results will be 
analyzed by SPSS statistical software.  
RESULTS 
Our study was a Cross-sectional study conducted among 100 
Type-II diabetic patients between 30-50 years of age. 
Two group were assigned according to the severity of 
Diabetic Retinopathy. One is a mild grade and another is a 
moderate grade. 
NLR, RDW and RBC count were analyzed in this study 
population. Also HBAIC and blood glucose levels were correlated 
with them. 
Statistical analysis was done with SPSS Software. Results 
were studied using unpaired t-test, chi-square test and Pearson 
coefficient Correlation. 
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CONCLUSION 
From our study we conclude that, both NLR and RDW are 
useful markers of vascular inflammation for  
1) Early diagnosis of Non-proliferative diabetic retinopathy.  
2) Assessing the severity of non proliferative Diabetic 
Retinopathy as mild or moderate grades.  
3) Also their prediction of uncontrolled glycaemic status since 
they correlate well with HBA1C and blood glucose levels. 
KEY WORDS 
Red Blood Cell, Vascular Inflammation, Diabetic 
Retinopathy. 
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INTRODUCTION 
Diabetes Mellitus is a group of metabolic disorders 
characterized by hyperglycemia which results from either defect in 
insulin secretion, insulin action or both. 
According to International diabetes Federation, globally 381 
million people have Diabetes. The disease affects 62 million 
Indians which is more than 7.1% of adult population and nearly one 
million people die due to diabetes ever year. 
Blindness is 25 times more common in diabetics than non-
diabetics. Diabetic retinopathy ranks the sixth common cause of 
blindness in India. Prevalence of Diabetic retinopathy in patients 
with diabetes was recently estimated to be 34.6%. 
Ocular fundus examination every year by an ophthalmoscope 
is the most important clinical assessment in a diabetic patient to 
detect Diabetic Retinopathy. But accessability and awareness to 
undergo such an examination is lacking both in the diabetic 
population and among the medical practitioners. 
Recently vascular inflammation is proposed as the basic 
pathogenic mechanism behind diabetic microvascular 
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complications. And hence detection of markers for vascular 
inflammation can help us to diagnose diabetic microangiopathy 
particularly diabetic retinopathy very early, so that active 
intervention in that stage would prevent a diabetic patient from 
becoming blind. 
Many pathophysiological disorders have been involved in the 
development of diabetic retinopathy but the most common are 
Rheological disorders of Red Blood cells and decreased RBC 
deformability. 
Hence in this study we would like to investigate the 
association of Red Cell distribution width, Red blood cell count and 
Neutrophil/ Lymphocyte ratio with mild to moderate non 
proliferative diabetic retinopathy. 
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REVIEW OF LITERATURE 
INTRODUCTION 
Diabetes Mellitus1 has been defined as a “Group of Metabolic 
disorders characterized by hyperglycemia resulting from defects in 
Insulin Secretion, Insulin action or both”. The most common type, 
Type-II Diabetes Mellitus results from a combination of genetic 
and acquired factors. Prevalence of Type-II Diabetes is increasing 
globally and has reached epidemic proportion in many countries 
especially in India.  
EPIDEMIOLOGY 
According to the International Diabetes Federation3,4 the total 
number of adult Type-II Diabetes in the world was estimated as 366 
million in 2011 which was projected to increase to 552 million by 
2030(1). Among the top 10 countries with the larger number of 
diabetic adults, five are in Asia. China tops the list with 90 million 
followed by India with 61.3 million diabetic population. The 
numbers are estimated to rise to 129.7 million and 101.2 million 
respectively by 2030. 
The most important predictor of morbidity and mortality2 in 
Type-II Diabetes is the control of blood sugar levels. And even 
 4 
with adequate control of blood sugars, patients with Type-II 
Diabetes with more than 10-15 years duration of disease are more 
prone to develop both micro and macro vascular complications. 
Hence regular screening for complications apart from blood sugar 
control is the most important determinant for morbidity in diabetes 
mellitus. Among the micro and macro vascular complications, 
retinopathy is a major cause of morbidity in patients with diabetes. 
It is a major cause of blindness even in the most industrialized 
nations. The prevalence of diabetic retinopathy is nearly 50-80% in 
Type-II Diabetes after 20 years of duration of disease. And the 
incidence of blindness in Type-II Diabetes is 25 times higher when 
compared to the general population. 
A causal association between glycemic control and the 
development and progression of microvascular complications in 
diabetes particularly retinopathy has been suggested from studies in 
both animals and humans. These associations were confirmed in the 
prospective Diabetic control and complications Trial (DCCT)2. 
Before going into the pathogenesis and pathophysiology of 
Diabetic Retinopathy, an overview of vascular complication in 
Diabetic Type-II is presented here. 
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Overview of vascular complications in Type-II Diabetes 
Many factors play a pivotal role in the initiation and 
progression of vascular disease in Type-II diabetes. Out of these 
factors, two are very important. 
1) Mitochondrial dysfunction and insulin resistance. 
2) Beta-Cell failure. 
MITOCHONDRIAL DYSFUNCTION AND INSULIN 
RESISTANCE 
The main culprit for the development of metabolic syndrome 
is insulin resistance. This is always associated with 
hyperinsulinaemia11. 
Insulin resistance induces multiple metabolic alterations 
through various mechanisms. 
Factors that contribute to insulin resistance are  
1) Genetics 
2) Obesity 
3) Physical inactivity 
4) Advancing age 
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Metabolic complications that occur commonly in patient with 
insulin resistance are 
1) Atherogenic dyslipidemia 
2) Hypertension 
3) Glucose intolerance 
4) Prothrombolic state 
Defect in insulin action12 is present in many tissues but mainly in 
1) Liver  
2) Adipose tissue 
3) Skeletal muscle 
The main defects underlying insulin resistance are  
1) Impaired insulin signaling 
2) Intracellular defects in glucose metabolism. 
Intracellular defects in glucose metabolism are multiple and 
the major one among them leading to insulin resistance is the role 
of free fatty acids with underlying mitochondrial dysfunction. 
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FREE FATTY ACIDS AND MITOCHONDRIAL 
DYSFUNCTION IN TYPE-II DIABETES 
The main source of fuel in skeletal muscles are free fatty 
acids. More than 96% of ATP8 production is derived from free fatty 
acids mainly during exercise. In Type-II Diabetic individuals the 
oxidation of FFAS in skeletal muscle is impaired secondary to an 
abnormality in oxidation capacity of the mitochondria. 
Insulin function is impaired slowly in insulin resistant 
individuals. Mainly the suppression of lipolysis is first affected 
leading to enhanced production and circulation of free fatty acids. 
The resultant free fatty acid influx into the skeletal muscle raises 
their intramuscular concentration. 
Since the mitochondrial oxidative capacity is already 
deranged, there will be enhanced production of intramyocellular 
fatty acid metabolites like DAG, ceramides and other toxic lipid 
metabolites. These toxic metabolites produce serine kinase pathway 
activation. The production of serine kinase directly interfere with 
intracellular insulin signalling. These kinases also produce defects in 
the multiple intracellular steps involved in glucose metabolism like 
1) Glucose transport 
2) Glucose phosphorylation 
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3) Glycogen synthesis 
4) Glucose oxidation. 
CONTRIBUTION OF EXPERIMENTAL STUDIES9 
Experimental studies in human skeletal muscle have 
documented the clear defect in mitochondrial oxidative 
phosphorylation and electron transport as the cause of insulin 
resistance by various molecular, biochemical and magnetic 
Resonance spectroscopic techniques. Impaired ATP synthesis is 
also documented by nuclear magnetic resonance  guided 
measurement of oxidative phosphorylation. The NMR also shows a 
30-40% reduction in the resting metabolic flux through the cycle 
and oxidative phosphorylation in the lean, normal glucose tolerant, 
insulin resistant offspring of subjects with Type-II Diabetes. 
Subjects with Type-II diabetes also have  
1) Reduced exercise tolerance 
2) Impaired recovery of intracellular phosphocreatine 
concentration in skeletal muscle following exercise. 
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These results indicate clearly that the defect in mitochondrial 
oxidative phosphorylation contribute significantly to reduced 
exercise capacity in individuals with insulin resistance. 
Normal aging process is also associated with insulin 
resistance through a reduction in the mitochondrial ATP synthesis 
rate and increase in the intracellular fat content. Finally all these 
steps results in a vicious cycle by further decreasing the oxidative 
phosphorylation flux in the skeletal muscle. So regardless of 
etiology insulin resistance is directly due to impaired mitochondrial 
oxidative phosphorylation. 
RESULTS 
The mitochondrial defects identified are  
1) Reduction in the number of mitochondria with normal 
function of individual mitochondria. 
2) Intrinsic defect in the quantitatively normal number of 
mitochondria. 
3) Some combination of the above 
These defects can be both inherited or acquired. But this 
question is unanswered for more than a decade. Normally if the 
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defect is acquired it can be reversed or prevented while the 
inherited defect is permanent. 
MITOCHONDRIAL DEFECTS IN INSULIN RESISTANCE: 
CAUSE OR EFFECT 
The mitochondrial defect in oxidative phosphorylation 
described with invivo MRS showed isolated mitochondrial defect 
could contribute to the increase in intramyocellular free fatty acid 
metabolite levels observed in obesity and Type-II diabetes and can 
contribute to insulin resistance. If the increase in intramyocellular 
fat content in insulin resistant individuals led to an increase in fat 
oxidation and production of reactive oxygen species and other toxic 
reactive metabolites, then the decrease in oxidative pathway for 
phosporylation leads to mitochondria function down regulation and 
amelioration of the production of toxic metabolites. 
Over expression of PGC-1 alpha gene in the skeletal muscle 
of mice enhances mitochondrial activity, expression of proteins 
involved in mitochondrial fatty oxidation and also insulin 
stimulated glucose disposal and uptake in skeletal muscle. 
Activation of sirtuin-1 with reseveratrol in mice led to an 
increased oxidative phosphorylation in mitochondria and also 
protected the mice from diet induced obesity and insulin resistance. 
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Down regulation of mitochondrial function in myotubules 
with the help of oligomycin or ethidium bromide increased the 
mitochondrial fat content and also led to impairement of insulin 
signaling and reduced glucose disposal. But the treatment of the 
muscle cells with Azide, an inhibitor of mitochondrial complex-II 
led to increased basal glucose uptake without affecting the insulin 
stimulated glucose uptake in myotubules. 
Down regulation of electron transport chain activity in mice 
by knocking down initiating factors led to increased insulin 
resistance and protection from fat induced insulin resistance. 
Hence to conclude from the above studies  
1) Defective oxidative phosphorylation in mitochondria is the 
culprit for the development of impaired insulin action in 
various insulin resistant states including Type-II diabetes, 
obesity and normal aging process. 
2) Excessive FFA supply result in increased intramyocellar fat 
content in insulin sensitive tissues which in a backdrop of 
impaired fatty acid oxidation led to the accumulation of toxic 
lipid metabolites leading to insulin resistance. 
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BETA CELL FAILURE IN TYPE-II DIABETES 
Even though insulin resistance is the major contributor for 
disease progression in diabetes, it is the decline of beta cell 
function that determines the rate of the disease progression. 
The established support for the above said statement can be 
obtained from the (UKPDS) United Kingdom prospective diabetes 
study. 
RESULTS FROM UKPDS 
A 50% reduction of beta cell function (assessed by HOMA-
IR) was present in newly diagnosed patients enrolled in the study at 
the initial period. But after a 10 years follow up, not much change 
was observed in the insulin resistance irrespective of treatment. The 
level of beta cell function followed a linear decline. 
RESULTS FROM BELFACT STUDY 
According to the belfact diabetes study, subjects developing 
diabetes have a near 60% reduction of beta cell function at the 
initial stage itself. Thereafter beta cell failure follows 2 phases. 
Phase-A 
It precedes overt diabetes and it is further characterized by a 
slow but constant decline in beta cell function of around 2% per year. 
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Phase-B 
It occurs after the development of overt hyperglycemia and is 
characterized by an accelerated decline in beta cell function of 
around 18% per year. 
Hence initial alteration in beta cell function reflects intrinsic 
defects and the accelerated beta cell decline is the consequence of 
glucotoxicity and lipotoxicity. So a vicious cycle develops after the 
disease gets manifested. 
MECHANISM UNDERLYING BETA CELL FAILURE 
Reduction in beta cell mass is associated with increased 
apoptosis and increased expression of caspase 3 & 8. These 
caspases are mediators of apoptosis. The reduction in Beta cell 
function and mass is virtually apparent at the time of diagnosis of 
impaired glucose tolerance indicating that there is  preexisting 
intrinsic beta cell defect. 
Several genetic variants have been identified in the 
pathogenesis of beta cell decline. OF these 2 are important 
1) Genetic variants of transcription factor _alpha  
2) Single nucleotide polymorphisms 
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So a genetic predisposition is always associated with initial 
beta cell defect which when subjected to increased demand in a 
case of insulin resistance and obesity leads to overt beta cell 
failure, development of glucose intolerance and progressive 
worsening of glycemic control. The 2 main factors which underlie 
beta cell failure apart from genetic predisposition are 
1) Glucotoxicity 
2) Lipotoxicity 
GLUCOTOXICITY 
Persistently high-blood glucose concentration impairs insulin 
sensitivity and also beta cell function. This phenomenon is known 
as glucotoxicity. This is usually a reflection of oxidative stress 
secondary to generation of mitochondrial ROS. Excessive 
mitochondrial ROS is as a result of enhanced glucose metabolism. 
Major markers of oxidative stress are 
1) Nitrotyrosine 
2) 8-hydroxy- 2- deoxyguanosine 
There is an inverse relationship of these markers to glucose 
stimulated insulin release. Even intermittently elevated glucose 
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level impair glucose stimulated insulin secretion and also they 
activate apoptosis and bring about alteration in mitochondrial 
morphology and density together with increased intracellular 
nitrotyrosine content. Hence glucose fluctuation in response to meal 
in  prediabetic patients can cause loss of functioning beta cell mass. 
Persistant and long standing hyperglycemia results in chronic 
stimulation of beta cell and increased insulin synthesis. This can 
lead to stress of endoplasmic reticulum. Normally the endoplasmic 
reticulum is responsible for the production, modification and 
delivery of proteins to their target sites. Hence under condition of 
ER stress these process get impaired. 
Usually ER stress is offset by enhancement of its folding 
capacity via modulation of foldases followed by chaperones. Also 
there will be downregualtion of the biosynthesis load and increased 
clearance of unfolded proteins. These processes usually initiate 
apoptosis. 
LIPOTOXICITY 
Obesity is the central component of metabolic syndrome and 
it is always accompanied by dyslipidemia and elevated 
inflammatory adipocytokines and leptin. These cytokines affect 
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insulin sensitivity and can also initiate apoptosis. Apoptosis in turn 
stimulates the inmate immune system through mobilization of T 
cells leading to auto immune mediated destruction of beta cells and 
their loss of function. 
PATHOPHYSIOLOGICAL EFFECTS OF FFAS 
1) Long term elevation of FFAS inhibit beta cell function and 
also lead to accumulation of toxic lipid metabolites. This 
process is classically known as Lipotoxicity. 
2) Chronic exposure to increased FFA levels attenuates the 
glucose- stimulated insulin secretion. 
3) FFAs can stimulate apoptosis of beta cells via activation of 
caspases secondary to enhanced ceramide formation within 
the beta cells. 
4) FFAs can induce down regulation of Akt- Phosphorylation 
leading to defective insulin signaling and also initiation of 
apoptosis. 
5) FFAs also induce the expression of iNOS leading to enhanced 
production of Nitric oxide resulting in defective insulin 
signaling. 
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6) FFAs can also stimulate increased production of reactive 
oxygen species and this can result in oxidant damage of the 
beta cell mass. 
AMYLOID 
Islet amyloid polypeptide is a normal beta cell secretary 
product and in Type-II diabetes there will be increased deposition 
of IAPP diffusely throughout the pancreatic islet leading to 
progressive reduction in beta cell mass, function and glucose 
intolerance. 
PATHOGENESIS OF DIABETIC RETINOPATHY 
The mechanism by which retinopathy occurs in diabetes are 
multifactorial. The risk factors are also plenty. 
Risk factors for the development of diabetic 
retinopathy2,4,5,6,7. 
DURATION OF DIABETES 
It is the best predictor of diabetic retinopathy. Studies have 
reported that after 20 years of diabetes, nearly 99% of patients with 
Type-I1 and 60% of Type-II have some degree of Diabetic 
Retinopathy. 
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AGE 
Diabetic Retinopathy is more frequent in the order onset 
group. 
HYPERGLYCEMIA 
Numerous studies have shown that, an average reduction of 1-
1.5% in HbA1C can cut down the risk of retinopathy by 40%, 
progression to vision threatening retinopathy by 25%, need for laser 
therapy by 25% and blindness by 15%. 
SYSTEMIC HYPERTENSION 
It is a major contributor for the development of retinopathy in 
the setting of uncontrolled diabetes mellitus. Numerous studies 
have shown that an increase in systolic blood pressure of 10 mmHg 
increase the risk of early diabetic retinopathy by 10% and 
proliferative diabetic retinopathy by 15%. 
RENAL DISEASE 
Nephropathy is a fore runner of diabetic retinopathy and 
nearly 35% of patients with retinopathy have elevated renal 
parameters and proteinuria. 
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PREGNANCY7 
Risk of developing retinopathy is around 10% during 
pregnancy for a women with diabetes and it is further complicated 
by the presence of hypertension and if so there will be progressive 
disease. Some people will have regression of retinopathy after 
delivery. 
ETHNICITY5,6 
Prevalence of diabetic retinopathy is reported to be higher in 
African Americans, Hispanics and South Asians than in white 
people. 
OTHER MINOR RISK FACTORS 
Many other minor risk factors also contribute to the 
development and progression of diabetic retinopathy like smoking, 
consumption of alcohol, body mass index, physical activity, 
cataract surgery, dyslipidemia and so on … 
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PATHOPHYSIOLOGY10 
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The mechanism by which glycemic control leads to vascular 
disease is not clearly understood. There is a loss of retinal pericytes 
and endothelial cells of microvasculature which starts at an early 
stage in diabetes and when coupled with the thickening of basement 
membrane heralds the onset of diabetic retinopathy. Death of the 
pericytes in the retina and cells of the microvasculature along with 
the impairment of basement membrane function leads to the 
formation of microaneurysms, increased vascular permeability and 
increased activity of vasoproliferative substances. 
VASCULAR ALTERATIONS IN DIABETIC RETINOPATHY 
Impairment of Retinal Blood Vessel Autoregulation14,15 
Normally the retinal capillaries are lined by pericytes and 
endothelial cells. Endothelial cell layer is a single one lying on a 
basement membrane and they are linked by tight junctions 
constituting the inner blood retinal barrier. Hence endothelial cell 
layer damage leads to enhanced vascular permeability. 
The pericytes16,18 are present on the endothelial cells and they 
envelop the capillaries. Their main function is contractile and hence 
they regulate the retinal capillary perfusion. Pericyte damage leads 
to abnormal autoregulation of blood flow in retina and weakening 
of the capillary walls leading to a saccular outpouching called 
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microaneurysm and they are the earliest sign of diabetic 
retinopathy6,8,9,16. 
Weakening of capillary walls leads to the formation of 
microaneurysm22 and their rupture leads to intraretinal hemorrhage. 
In fundus fluorescein angiography microaneurysms will be 
hyperfluorescent and intraretinal haemorrhages will be 
hypofluorescent. 
Further abnormal autoregulation leads to increased vascular 
permeability leading to increased deposition of extracellular matrix 
component called hard exudates resulting in basement membrane 
thickening of the capillaries in retina and also can cause retinal 
edema. Ultimately these process can lead to loss of vision. 
Progressive retinal vascular disease results in hypoxia 
secondary to retinal capillary closure and the resultant infarction of 
the nerve fibre layer leads to the formation of what so called cotton 
wool spots. Also these will be concomitant obstruction in the 
axoplasmic flow. 
Abnormalities in the venous system of the retina also occurs 
leading to the formation of loops, beading and dilatation. These 
changes signify retinal ischaemia. 
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NEOVASCULARISATION28 
Development of new vessels in retina (Neovascularisation) 
occurs in the advanced stages of DR. 
Retinal ischemia described earlier is the potent stimulator of 
new vessel proliferation through the activation of angiogenic 
factors particularly VEGF. 
New vessel formation within the retinal tissue or endothelial 
proliferation within the pre-existing vessels is represented by the 
term (IRMA) intraretinal microvascular abnormalities. 
Major biochemical mechanisms that modulate the 
pathogenesis of DR operate mainly by exerting their effects on 
cellular metabolism, cell signalling and expression of growth 
factors. 
MAJOR BIOCHEMICAL PATHWAYS UNDERLYING DR 
PATHOGENESIS 6,8,9,16 
Aldose Reductase 
Chronic hyperglycemia causes enhanced production of 
sorbitol from glucose by the enzyme aldose reductase. 
Accumulation of sorbitol intracellularly causes osmotic damage to 
the retinal endothelial cells and also to the pericytes. 
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Protein Kinase C 
Activation of PR-C occurs secondary to uncontrolled blood 
sugar levels resulting in enhanced expression of matrix proteins and 
vaso active mediators. 
Both matrix proteins and vasoactive mediators cause 
thickening of basement membrane and enhanced vascular 
permeability 
ADVANCED GLYCATION END PRODUCTS (AGE) 
Glycosylation of serum and tissue proteins occurs in the 
setting of chronic hyperglycemia resulting in the formation of 
AGEs. 
AGE products increase vascular permeability, stimulate cell 
proliferation and also they can promote the influx of mononuclear 
cells leading to inflammation. 
Net result of increased circulating AGEs lead to loss of 
pericytes, damage to endothelial cells and also formation of 
microaneurysm. 
OXIDATIVE STRESS 
Chronic hyperglycemia leads to increased production of 
(ROS) Reactive Oxygen Species. 
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Increased ROS promotes progression of DR mainly by 4 
mechanisms. 
 Activation of protein kinace-C 
 Activation of Polyol Pathway 
 Increased production of VEGF 
 Increased Formation of AGEs 
VEGF 
Retinal ischaemia and concurrent hypoxia stimulates the 
production of VEGF. 
VEGF causes both angiogenesis and increased capillary permeability. 
RENIN ANGIOTENSIN SYSTEM: (RAAS) 
Upregulation of local RAAS in retina occurs in chronic 
hyperglycemia and increased angiotensin II stimulates VEGF expression. 
Erythropoietin 
Retinal ischaemia enhances the production of erythropoietin 
which promotes angiogenesis independent of VEGF. 
Carbonic Anhydrase 
Extracellular carbonic anhydrase levels increases in DR 
resulting in elevation of PH leading to increased vascular 
permeability. 
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Growth Hormone (GH) and Insulin like growth factors 
GH and IGF levels are elevated in retinal hypoxia and they 
modulate the function of endothelial precursor cells leading to 
angiogenesis. 
Further IGF causes disruption of blood retinal barrier and 
causes retinal edema by increasing vascular permeability. 
Inflammation 
Finally the latest updation in the pathogenesis of DR is the 
proposal of vascular inflammation as the main culprit. 
Retinal endothelial cells and neural cells in response to 
inflammation causes increased production of VEGF and also 
recruitment of inflammatory mediators. 
These mediators enhance vascular permeability, 
neurodegeneration and neovascularization. 
Classification of Diabetic Retinopathy61 
Diabetic Retinopathy is divided into two main forms 
1. Non proliferative DR 
2. Proliferative DR 
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Classification of DR is mainly based on the presence of 
(IRMA) intra retinal microvascular abnormalities and 
neovascularization. Various classification systems are available but 
used in current scenario were three of them. 
ETDRS CLASSIFICATION SYSTEM20,21 
Disease 
severity 
level 
Findings observable upon dilated ophthalmoscopy 
Mild NPDR Presence of at least one microaneurysm 
Moderate 
NPDR 
Presence of haemorrhage / microaneurysm, cotton 
wool spots (CWS), venous beading (VB) and IRMA 
but less than that of severe NPDR 
Severe 
NPDR  
(4-2-1) 
Haemorrhages and microaneurysms in 4 retinal 
quadrants 
VB in at least 2 retinal quadrants 
IRMA in at least 1 retinal quadrant 
Early PDR New vessels. Criteria not met for high-risk PDR 
High-risk 
PDR 
Neovascularization on or within one disc diameter of 
the optic disc (NVD), with or without vitreous or 
preretinal haemorrhage; or Neovascularization 
elsewhere (NVE) and vitreous and/or preretinal 
haemorrhage 
Advanced 
PDR 
Posterior fundus obscured by preretinal or vitreous 
haemorrhage; or Center of macula detached 
The gold standard for assessing DR is the airlie house 
classification system. This involves the grading of seven 300 
stereoscopic images of the retina comparing with standard 
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photographs. Recently this system is modified and updated as “The 
early treatment of diabetic retinopathy study” (ETDRs) 
Classification. 
INTERNATIONAL CLASSIFICATION SYSTEM34,62 
Developed by the American Academy of ophthalmology 
(AAO) to improve the communication between primary care 
physicians and ophthalmologists. 
Proposed disease severity 
level 
Clinical findings (on dilated 
ophthalmoscopy) 
No apparent retinopathy No abnormalities 
Mild NPDR Microaneurysms only 
Moderate NPDR More than just microaneurysms but less 
than severe NPDR 
Severe NPDR Any of the following 
>20 intraretinal haemorrhages in 4 
retinal quadrants; 
Definite VB in >2 retinal quadrants; or 
Prominent IRMA in > 1 retinal 
quadrant 
PDR One or more of the following 
Neovascularization; 
Vitreous haemorrhage; or 
Preretinal haemorrhage 
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CLINICAL FEATURES 
Diabetic Retinopathy in its earlier stages is entirely 
asymptomatic and it is very prudent to screen for the signs of 
retinopathy in every diabetic patient regularly. The changes seen in 
Diabetic Retinopathy are divided into two important categories. 
1) Non proliferative diabetic retinopathy (NPDR) 
2) Proliferative Diabetic Retinopathy (PDR). 
NON PROLIFERATIVE DIABETIC RETINOPATHY 
It is characterized by five important clinical findings 
1) Retinal capillary microaneurysms 
2) Haemorrhages 
3) Hard exudates and retinal edema 
4) Cotton wool spots 
5) Venous beading and IRMA 
MICRO ANEURYSMS 
Saccular outpouchings of the capillary wall in the retina along 
with hypercellularity constitute microaneurysms. On 
ophthalmoscopic examination they will be identified as Red 
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coloured dots. But usually the best identification technique for 
microaneurysms is fundus fluorescein angiography. Micro 
aneurysms are the earliest detected fundus abnormality in Type-2 
Diabetic patients. 
RETINAL HAEMORRHAGES 
Retinal haemorrhages are divided into two types. 
1) Dot-Blot Haemorrhages 
2) Retinal nerve fibre layer haemorrhages 
Dot-blot haemorrhages 
These are punctate haemorrhages within the retina intra 
retinally and they usually arise from the capillaries at their venous 
terminal. They appear as red dots compactly damaged within the 
middle layers of retina. 
Small dot-blot haemorrhages appears like microaneurysms on 
ophthalmoscopic examination and the best differentiating 
investigation is fundus fluorescein angiography. 
Retina nerve fibre layer haemorrhages 
These are otherwise known as flame shaped haemorrhages. 
Their alignment to the retinal nerve fibre layer will be more or less 
horizontal. They originate from the precapillary arterioles located 
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superficially within the retinal nerve fibre layer. These flame 
shaped haemorrhages actually indicate the presence of systemic 
hypertension or co-added venous obstruction. 
Hard Exudates and retinal edema 
Leakage of lipoproteins from the tight junctions of 
endothelium in the retinal capillaries give rise to lipid deposits 
what are known as hard exudates. They are yellowish deposits 
situated intraretinally in a circinate pattern around micro 
aneurysms. 
Breakdown of the retinal blood barrier leads to increased 
capillary permeability resulting in retinal edema. This edema is 
always accompanied by hard exudates and usually they tend to 
occur in the macular region. 
Cotton Wool Spots 
Cotton wool spots are soft, yellowish, superficial fluffy 
lesions and they are otherwise known as soft exudates. They tend to 
occur in the areas of localized capillary ischemia. As a result of 
ischaemia, the axoplasmic transport within the nerve fibre layer 
gets obstructed focally leading to the accumulation of neuronal 
debris. These neuronal debris clinically resemble cotton wool spots 
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and they tend to obscure the underlying blood vessels in the region 
of the nerve fiber layer. 
VENOUS BEADING AND IRMA 
Saccular outpouching of venous walls are called venous 
beading. They tend to occur with increased frequency in the areas 
of capillary non- perfusion. They also manifest as venous loops in 
these areas. 
Intra retinal microvascular abnormalities or IRMA are 
capillary dilatations and they usually function as collateral channels 
in the areas of capillary non-perfusion. 
Both IRMA and venous beading are signs of enhanced retinal 
ischaemia and they usually reflect the severity of capillary 
hypoperfusion. 
PROLIFERATIVE DIABETIC RETINOPATHY 
Retinal neovascularization is the hallmark of proliferative 
diabetic retinopathy. About 50 % of patients with non proliferative 
diabetic retinopathy of severe grade progress to proliferative stage 
almost within a year. Almost one fourth of their retina should be 
non perfused before the development of proliferative diabetic 
retinopathy. 
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The stage of proliferative diabetic retinopathy is 
characterized by 2 findings: 
 Neo vascularization. 
 Vitreous / pre – retinal hemorrhages. 
NEO-VASCULARISATION 
It is defined as the appearance of multiple new fine vessels 
arising either from the disc, retina or iris. It is the hallmark of 
Proliferative Diabetic Retinopathy. These new vessels are classified 
as NeoVascularisation of the Disc or NeoVascularisation Elsewhere 
according to their Origin. 
NEO-VASCULARIZATION OF THE DISC (NVD)52 
New vessels originating either from the disc or within one 
disc diameter from the optic nerve are known as Neo 
Vascularization of the Disc (NVD). 
Neo-vascularization Elsewhere (NVE): 
New vessels originating more than one disc diameter from the 
optic nerve are known as Neo Vascularization Elsewhere (NVE). 
SIGNIFICANCE OF NVD AND NVE58  
The blood vessels in NVD and NVE are not like normal 
retinal vessels. They are very fragile and more prone to rupture 
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easily causing leakage into the vitreous leading to formation of 
vitreous or pre- retinal hemorrhages. As the new vessel mature, the 
fibrous component becomes more prominent. The collagen scaffold 
contracts and elevates the underlying retina leading to tractional 
retinal detachment. 
VITREOUS OR PRE – RETINAL HAEMORRHAGES (PRH): 
Pre – retinal hemorrhage occur in the space between internal 
limiting membrane of retina and posterior hyaloid face. These 
hemorrhages are classically boat shaped. 
SIGNIFICANCE OF PRH  
Small pre-retinal hemorrhages can cause floaters but when 
they are found more extensive, sudden and painless loss of vision 
can occur. 
THE STAGE OF ADVANCED DIABETIC EYE DISEASE: 
Retinal detachment, rubeosis iridis and secondary glaucoma 
complete the picture of advanced End – stage diabetic 
retinopathy. 
Two types of retinal detachment occur 
 Those due to traction called as Non – Rhegmatogenous 
Retinal Detachment.  
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 Those due to the formation of new holes in the retina where 
ischaemia is prominent called as Rhegmatogenous Retinal 
Detachment. The holes are formed in the ischaemic areas by 
extensive tissue break down. 
DIAGNOSIS OF DIABETIC RETINOPATHY50  
The diagnosis of both Non – proliferative and Proliferative 
diabetic retinopathy includes a detailed medical history and a 
thorough ophthalmic examination. 
HISTORY 
Proper consideration should be given to  
1) Duration of diabetes. 
2) Ocular History: Trauma / Surgery for refractive error 
correction / laser treatment / ocular injections                       
3) Glycaemic control in the past ( HbA1c ) 
4) Medications. 
5) Other comorbid conditions (renal diseases, obesity, Systemic 
hypertension, dyslipidemia) etc.    
SYMPTOMS  
The patient’s quality of vision should be investigated to elicit 
symptoms like. 
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1) Blurred, distorted or fluctuating vision. 
2) Double vision. 
3) Night blindness.        
4) Floaters or flashes. 
OPHTHALMIC EXAMINATION53 
 Initial examination. 
 Ancillary test. 
INITIAL OPHTHALMIC EXAMINATION 
 Includes the assessment of visual acuity, Gonioscopy and slit 
lamp microscopy. 
(i)  Visual acuity 
Visual acuity is assessed after pupillary dilatation. Before 
dilating the pupil, it is always prudent to recognize rubeosis iridis 
or neovascularization of iris. Pupillary dilatation is achieved by 
administration of either 0.5% to 1% Tropicamide or 2.5% 
Phenylephrine. 
 (ii) Gonioscopy  
In the presence of rubeosis iridis or elevation of intra ocular 
pressure, gonioscopy is performed to rule out neo vascularization  
of the anterior chamber angle. 
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 (iii)  Slit –lamp biomicroscopy  
Retinopathy changes in the mid peripheral retina and 
posterior pole is best assessed by Slit lamp bio-microscopy. This 
can be done with the help of accessory lenses and when this 
examination is accompanied with a contact lens, visualization of 
peripheral retina will be of superior quality. 
ANCILLARY TEST 
 (i)  Color Fundus Photography (CFP)  
This is a very useful investigation in documenting the 
progression of retinopathy and also the response to treatment. 
Hence, this test is recommended in all clinical research studies in 
diabetic retinopathy. The main disadvantage of this test is that, it is 
not useful in the early stages of diabetic retinopathy with minimal 
fundal changes. 
(ii) Optical Coherence Tomography (OCT) 
Quantification of retinal thickness, identification and 
monitoring of macular edema, vitreo macular traction in selected 
patients with Diabetic Macular Edema can be done by Optical 
Coherence Tomography. 
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 OCT is useful for imaging the retina, subretinal space and 
vitreo-retinal interface with the help of high resolution (10 
micron) imaging. 
 OCT guided measurement of thickness of the retina is not 
precise sometimes and it correlates poorly with visual acuity. 
 (iii) Fundus Fluorescein Angiography ( FFA ) 
 FFA is the gold standard investigation for the diagnosis of 
both non proliferative and proliferative DR. 
 FFA can identify macular capillary non–perfusion, capillary 
leakage and their sources leading to macular edema as 
possible explanation for visual loss. 
 FFA can identify even subtle neo vascularization before other 
investigations. 
 FFA can be used as a mean of evaluating the source of 
unexplained visual loss. 
 FFA is always useful for documentation of the retinal lesions 
before laser pan – photo coagulation and also for follow up. 
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SCREENING RECOMMENDATIONS52 
Screening is the best possible way to prevent and reduce the 
progression of disease in diabetic retinopathy. Several methods 
have been proposed for screening of diabetic retinopathy. 
CLINICAL METHODS  
 Direct opthalmoscopy. 
 Indirect optholmoscopy. 
 Slit lamp biomicroscopy. 
PHOTOGRAPHIC METHODS 
  Mydriatic 
 Non Mydriatic 
 Polaroid Cameras 
 Digital Imaging 
Out of all investigations, the gold standard is seven field 
stereoscopic colour fundus photography. In all other investigations 
a large proportion of sight threatening retinopathy can be missed. 
LIMITATIONS OF THE AVAILABLE SCREENING TESTS 
1) All screening test could be done only with the help of a peson 
with expertise in ophthalmology. 
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2) Most of the screening tests are incomplete and some changes 
can be missed on examination. 
3) Seven field stereo colour fundus photography and fundus 
fluorescein angiography which are considered as gold 
standard in the detection of DR are available only in 
specialized centres in ophthalmology / tertiary care centres so 
that mass screening of diabetic patients at risk could not be 
done. 
Hence in the search for a very simple tool in identifying 
diabetic retinopathy at the earlier stages without cumbersome 
procedures and at affordable cost, so that every diabetic patient can 
get benefitted from such an investigation either by mass screening 
programmes or regular screening at a local centre, the author here 
tries to elucidate the importance of Red cell distribution width, Red 
blood cell count and Neutrophil/ Lymphocyte ratio as the markers 
of vascular inflammation in the early diagnosis of Non proliferative 
DR. 
The author stresses here the imporotance of Red cell indices like. 
(1) RBC Count 
(2) Red Cell distribution Width 
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and also the (3) Neutrophil- Lymphocyte ratio in the early 
diagnosis of non proliferative diabetic retinopathy. Hence the 
author wants to brief the salient physiological, biochemical and 
pathological aspects of these indices in their contribution towards 
the diagnosis of NPDR. 
STRUCTURE OF THE RED CELL 
Mature RBCs are unique among the cells of human tissues, in 
that they normally lack nuclei and cytoplasmic structures such as 
Lysosomes, endoplasmic reticulum and mitochondria. Hence they 
cannot carry out protein synthesis, unable to undergo mitosis and 
mitochondrial oxidative reactions. RBCs are biconcave discs of 7-
8µ m in diameter, but their shape changes to a parachute- like 
configuration in the capillaries whose diameter, is less than that of 
RBCs in the biconcave disc form. The membrane of red cell is 
elastic and so they resume biconcave shape. Once they re-enter the 
large blood vessels, loss of flexibility or elasticity leads to 
membrane damage and change in shape leading to diminished life 
span. 
ORGANIZATION OF THE ERYTHROCYTE MEMBRANE 
The membrane and the cytoskeleton of the RBC are 
collectively known as stroma. The membrane is highly deformable 
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and non-expansile structure. Its integrity is firmly maintained by 
the attachment of its inner surface to a lattice like structure of 
specilized cytoskeletal proteins which support the membrane and 
also decides the shape of the RBCs. 
LIPIDS 
Phosphatidyl Choline 
Phosphatidyl Ethanolamine 
Phosphatidyl Serine 
Sphingomyelin 
These lipid molecules account for most of the phospholipids. 
The aminophospolipids lie in the inner cytoplasmic monolayer and 
the choline phosphatides lie in the outer monolayer. 
Membrane fluidity is taken care of by cholesterol making it 
more viscous when compared to pure phospholipid membranes. 
PROTEINS 
1) Transmembrane proteins 
2) Cytoskeletal proteins 
Transmembrane proteins 
The two predominant transmembrane proteins age (AE-1) 
anion exchanger and glycophorin -A (GPA). 
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FUNCTIONS OF AE-1 
 It encases the channels through which facilitated transport of 
glucose and anions take place. 
 It interacts with the cytoskeleton by binding to ankyrin, hence 
its mutation may lead to RBC membranopathies and structural 
defects interfering with the rheological properties of the 
RBCs. 
FUNCTIONS OF GPA 
 It is enriched with large amounts of sialic acid which 
contribute to the negative charge of the outer surface of the 
red cell at physiological PH. 
CYSTOSKELETAL PROTEINS 
 Spectrin 
 Actin 
 Ankyrin 
 Adducin 
 Protein 4.1, 4.9 
 Tropomyosin 
 Tropomodulin 
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The most important constituent of the cytoskeleton is 
spectrin. They are intertwined and linked together by other proteins 
forming a lattice like network which is attached to the internal 
surface of the membrane. Because of this resilient structure red 
cells resume their biconcave disc forms after their distortion forces 
have been removed. 
RELATIONSHIP BETWEEN RBC COUNT, 
ULTRASTRUCTURAL MEMBRANE ALTERATIONS AND 
MICROVASCULAR COMPLICATIONS59 
 Chronic hyperglycemia causes non enzymatic glycosylation 
of RBC membrane proteins. This decreases the negative 
surface electric charge so that there will be accelerated aging 
of RBCs. 
 Normally the negative charge leads to firm adhesion between 
surfaces causing electrostatic repulsion between the 
erythrocytes resulting in diminished aggregation. This also 
results in low-shear rate viscosity and yield stress of blood. 
 Hence the net result of reduction in negative surface charge 
increases microviscosity, aggregation and adhesiveness of 
RBCs. The decrease of surface charge leads to the collinear 
decrease of membrane deformability. 
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 The velocity of RBC movement comes to a stand still 
secondary to the reduction in the movement of RBCs through 
the capillary segments as a result of reduction on the net 
surface charge. 
 Mature and aged RBCs show more aggregability, 
deformability and increased mechanical fragility. 
 Haemoglobin molecules of some aging RBCs get aggregated 
and attaches to the inside of the cell membrane leading to the 
reduction in membrane flexibility. This greatly influences the 
oxygenation of Hb. 
 Reudced surface negative charges directly causes changes in 
the properties of the basement membrane of retina. These 
changes causes breakdown of the retinal- blood barrier 
leading to increased permeability of the capillaries resulting 
in exudation of proteins into the superficial and deep layers 
of the retina. 
 Normally phospholipid symmetry is maintained in the inner 
layer of the plasma membrane by increased concentrations of 
phophatidyl serine which contain a negative charge. This 
symmetry is distorted secondary to excessive oxidative stress 
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within the cell leading to externalization of the serine moiety. 
Hence this asymmetry and externalization renders the RBC 
surface as thrombogenic and these cells are removed by 
macrophages in circulation by way of phagocytosis. 
 The environment of abnormal RBCs, Phosphatidyl serine 
asymmetry and recruited leucocytes leads to enhanced 
coagulation cascade. 
 Anaemia causes tissue hypoxia leading to expression of 
growth factors from the already compromised kidney 
resulting in mitogenic and fibrogenic effects. 
 The decrease in RBC count may contribute to the microvascular 
complications by a reduced haemoglobin level also. 
 Reduced RBC count in the case of normocytic normochromic 
picture actually signals the damage that has occurred to the 
renal tubular interstitium and may herald the onset of diabetic 
nephropathy. 
RED CELL DISTIRBUTION WIDTH 
Red cell distribution width is an index of variation in RBC 
size or RBC volume. Normally red cell size variation is known as 
anisocytosis and RDW is a measure of extent of anisocytosis. 
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Most automated instruments produce a quantitative 
assessment of the variation in red cell volume indicated by RDW 
which corresponds to the microscopic analysis of the degree of 
anisocytosis. The RDW derived from pulse height analysis can be 
expressed either as (SD) standard deviation in fl or as the percent of 
coefficient of variation (CV) of the measurements of red cell 
volume. 
NORMAL REFERENCE RANGES OF RDW 
RDW – SD :  39-46 fl 
RDW-CV : 12-14% in adults 
RDW-SD 
It is a measurement of width of RBC size distribution 
histogram and it is measured by calculating the width at the 20% 
height level of the RBC size distribution histogram. Hence RDW-
SD is not influenced by the average RBC size (ie) mean corpuscular 
volume. 
RDW-CV 
It is calculated from standard deviation and MCV by the formula. 
RDW-CV (%) = 1 SD of RBC volume / Mcv x 100% 
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Since RDW- CV is obtained mathematically from MCV it is 
affected by changes in average size of RBCs. 
SIGNIFICANCE OF ELEVATED RDW 
 Early diagnosis of nutritional deficiency (d/t) iron, B12 and 
folic acid. 
 Differentiation of iron deficiency anaemia from thalassemia. 
 Differentiation of megaloblastic anaemia from other causes of 
macrocytosis. 
 Identification of Red cell fragmentation, agglutination and 
dimorphic red cells in peripheral smear examination. 
RED CELL DISTRIBUTION WIDTH IN NON-
PROLIFERATIVE DR 
 Increased RDW leads to reduced RBC deformability. 
This results in the impairment of blood flow through the 
microcirculation. 
 Elevated RDW is associated wih increased vascular 
inflammation and reduced level of anti oxidants. Hence 
RDW is considered as a global marker of oxidative 
stress and chronic inflammation. Inflammation 
influences deformability and half life of erythrocytes, 
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affects erythropoiesis, promotes anisocytosis and hence 
leads to elevation of RDW levels. 
 Increased RDW also reflect reduced negative surface 
electric charges which through already explained 
detailed mechanisms causes changes of non-
proliferative DR. 
NEUTROPHIL- LYMPHOCYTE RATIO 
Normally there are 4000-11000 WBCS/ micro litre in the 
human blood. Of these granulocytes are the most numerous. Young 
granulocytes have horse shoe shaped nuclei that become multilobed 
as the cells grow older. Most of them contain neutrophilic granules. 
NEUTROPHILS 
Neutrophils have cytoplasmic granules that contain 
biologically active substances involved in inflammatory reactions. 
The average half- life of a neutrophil in the circulation is 6 hours. 
They are attracted to the endothelial surface by selectins and they 
roll along it. Neutrophil adhesion molecules of the integrin family 
helps them to get bound to selectins. They insinuate themselves 
through the walls of the capillaries by a process known as 
diapedesis. Many of those that leave the circulation enter the GI 
tract and are lost from the body. 
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Neutrophilic granules contain various proteases and in 
addition they also contain enzymes such as NADPH oxidase, 
catalase and myeloperoxidases. NADPH oxidase is associated with 
a sharp increase in oxygen intake and metabolism in the neutrophil, 
what we call as the “Respiratory burst” and this reaction generates 
plenty of free O-radicals. The myeloperoxidase catalyses the 
conversion of Halides and cyanides to their corresponding acid 
forms. These acids inturn are potent oxidants by themselves. 
In addition to myeloperoxidase and NADPH oxidase 
neutrophil granules also contain an elastase and two 
metalloproteinases. 
The total body neutrophils can be divided into circulating 
pool (CGP) and marginating granulocyte pool. In these two pools, 
the cells are equal size and they are in constant equilibrium. MGP 
represents the neutrophils involved in adhesion and rolling along 
the endothelial cells in post capillary venules and they are not 
found in blood obtained by venepuncture. So the neutrophil content 
actually represents about half of the total no of neutrophils in the 
vascular compartment. 
LYMPHOCYTES 
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Lymphocytes are motile non phagocytic cells. There are many 
subpopulations of lymphocytes which interact with each other and 
with cells of the monocyte macrophage system. They help in 
maintaining both humoral and cell mediated immunity. 
Proliferating lymphocytes are enriched with enhanced levels of 
enzyme n-terminal deoxyribonucleic acid transferase. It is found in 
immature lymphoid cells in the bone marrow and thymocytes, but 
not in mature lymphocytes. Adenosine de aminase is present in 
large amounts in T-lymphocytes and it is necessary for their 
immune function. 
INFLAMMATION 
Inflammation is naturally a protective mechanism against 
invasion of microbes and toxins. The inflammatory response 
consists of 2 main components- a vascular reaction and a cellular 
reaction. Both the reactions are mediated by chemical factors that 
are derived from plasma proteins or cells produced as a result of 
inflammatory response. 
Chronic inflammation is of prolonged duration in which 
active inflammation, tissue destruction and repair are proceeding 
simultaneously. Atheroscleorosis and vascular disease are chronic 
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inflammatory processes of the arterial wall induced partly by 
endogenous toxic plasma lipid components. 
Morphological features of chronic inflammation 
 Mononuclear cell infiltration 
 Tissue destruction 
 Healing by connective tissue replacement 
 New blood vessel formation by elaboration of vascular 
endothelial growth factor and other angiogenic factors. 
 Fibrosis 
Most of these elements of chronic inflammation are found in 
the pathogenesis of both non proliferative and proliferative diabetic 
retinopathy. 
NLR IN SUBCLINICAL INFLAMMATION 
High Neutrophil lymphocyte ratio is a marker of subclinical 
inflammation in many disease states of the vascular system. NLR 
reflects the systemic inflammatory response that accompanies 
chronic disease but might also be influenced by systemic infections, 
atherosclerosis, hypertension, chronic renal disease and diabetes. 
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Subclinical vascular inflammation measured by derived NLR 
is linked with traditional risk factors of chronic diseases such as 
smoking, obesity, hypertension and elevated levels of triglycerides. 
MECHANISMS 
1) Endothelial dysfunction secondary to cellular response of 
blood components heralds the onset of inflammation. 
Endothelial dysfunction leads to impaired production of nitric 
oxide and prostacylins. This leads to the depletion of anti-
atherogenic, antithrombotic and vasodilator properties of the 
vascular endothelium. 
2) Diabetes Mellitus has been reported to the associated with 
acute phase response. In type-2 diabetes sialic acid, alpha-1 
acid glycoprotein, c-reactive protein, amyloid and 
interleukin-6 are increased. Also in parallel leukocyte count 
is elevated significantly than other markers indicating 
ongoing subclinical vascular inflammation. 
The normal d-NLR is < 2.0 in control population. 
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AIMS AND OBJECTIVES 
The aim and objective of the study is  
 To evaluate the usefulness of “Red Cell Distribution 
width, Red Blood Cell Count and Neutrophil / 
Lymphocyte ratio as potential markers of vascular 
inflammation in the early detection of non proliferative 
diabetic retinopathy”. 
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MATERIALS AND METHODS 
This is a cross sectional study and was conducted after 
Ethical Committee Clearance. 
The study composed of a total number of 100 subjects, all of 
them were Type-II diabetic patients enrolled into the study as cases. 
These subjects were from among the Type-II DM individuals 
attending the Diabetology and Ophthalmology Outpatient Clinic in 
Stanley Medical College Hospital, Chennai. 
Inclusion Criteria 
Cases Type-II Diabetic patients between 30-50 years 
diagnosed to have Mild to Moderate Non Proliferative 
diabetic retinopathy (Micro Aneurysm, Hard Exudate, 
Haemorrhage, Phlebopathy) 
Exclusion Criteria 
1) Type-II Diabetic Patients with Proliferative Diabetic 
Retinopathy, Micro/Macro Albuminuria, Established Diabetic 
Nephropathy, Chronic Kidney disease of any etiology. 
2) Type-II Diabetic patients with iron deficiency anaemia/ 
megaloblastic anaemia/ or recent blood loss. 
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3) Type-II Diabetic patients with any evidence of sepsis / 
infectious disease in prior 4 weeks. 
4) Type-II Diabetic patients with any form of arthritis on 
NSAIDS/ Active GI Ulcer. 
5) Type-II Diabetic Patients with Hypertension. 
SAMPLE COLLECTION  
Blood Samples 
A random sample was collected in the morning hours during 
the outpatient clinic time from the anticubital vein of the study 
subjects. The blood samples were analysed on the same day within 
4 hours of collection. The biochemical parameters relevant to the 
study were analysed by the following methodologies.  
Step-I: Estimation of RDW, RBC Count and NLR 
CBC WITH DIFFERENTIAL 
Test Method 
Sysmex XN and XS Systems: 
 WBC:  Flow cytometry 
 RBC:  Impedance counting 
 Platelet Count: Impedance counting 
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 Platelet F Count: Flow cytometry fluorescence count 
(performed when appropriate) 
 HGB:  Converted to SLS-hemoglobin and read photometrically. 
 MCV:  The average volume of individual erythrocytes derived 
from the RBC histogram. 
 RDW:  The size distribution spread of the erythrocytes 
population derived from the RBC histogram. 
 MPV:  The average volume of individual platelets derived 
from the PLT histogram. 
 HCT: Measured as a ratio of the total RBC volume to whole 
blood using cumulative pulse height detection. 
 MCH, MCHC:  Calculated parameters. MCH: Weight of HGB 
 in the average RBC. MCH = HGB ÷ RBC x 10 
MCHC: Average weight of HGB in a measured dilution. 
MCHC = HGB ÷ HCT x 100 
 WBC Differential: The instrument makes 3 measurements 
(volume, conductivity and scatter) as each cell passes through 
the flow cell. The low frequency impedance measurement 
defines cell volume. The high frequency conductivity 
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measurement indicates the internal conductivity. The light 
scatter measurement indicates the structure and shape. An 
algorithm is applied to determine different cell populations. 
 Abs Neutrophils, Abs Lymphocytes, Abs Monocytes, Abs 
Eosinophils, Abs Basophils: Calculated Parameters 
[Total WBC x (%Diff Analyte Result/100)] = Absolute Diff 
Analyte Count 
Reference Values 
RBC count Male  4.5 to 5.9 m/cumm 
RBC count Female  3.8 to 5.2 m/cumm 
Haemoglobin Male  13 to 18 g/dl 
Haemoglobin Female  11.5 to 16.5g/dl 
PCV Male  42 to 50% 
PCV Female  36 to 45% 
MCV 80 to 100 fl 
MCH 27 to 31 pg 
MCHC 32 to 36 g/dl 
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RDW-CV 11.6 to 14 % 
Total WBC Count 4000 to 11000 cells/ cumm 
Differential Count 
Neutrophils 40 to 75% 
Lymphocyte 20 to 45% 
Eosinophils 1 to 6% 
Monocyte 2 to 10% 
Basophils 0 to 1% 
Platelets Count 1.5 to 4.5 Lakhs / cumm 
MEASUREMENT OF HBA1C 
Technique 
Cation exchange high performance liquid chromatography. 
System 
The Biorad D10 haemoglobin Testing System. 
Procedure 
The Bio Rad D-10 Haemoglobin Testing System is the newly 
introduced fully automated analyzer based on Cation Exchange 
HPLC. The dual kit reorder pack contains whole blood primer, 
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calibrator 1 and 2, calibrator diluent, wash reagent, elusion buffer 1 
and 2 and analytical cartridge. The manufacturer’s instructions 
were followed for the quality control and calibration. This 
Technique requires no predilution or manual handling of patient’s 
samples. The samples are directly introduced in their primay tubes 
following calibrators and control samples. The instrument draws 
sample directly from the EDTA vacutainer and all processing of the 
sample is performed internally. Samples are automatically mixed, 
diluted and injected into the cartridge. The analyzer delivers a 
programmed buffer gradient of increasing ionic strength to the 
cartridge, where haemoglobins are separated on the bases of their 
ionic interactions. 
The separated haemoglobins are passed through flow cell of 
the filter photometer where changes in the absorbance at 415nm are 
measured. The run time is approximately 3 minutes per sample with 
a throughput of 20 samples per hour. A sample report and a 
chromatogram are generated for each sample. 
HB1AC 
Method :  Bio Rad HPLC  
Normal : 4 to 6% 
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Good Control : 6 to 7% 
Fair Control : 7 to 8% 
Poor Control : > 8% 
ESTIMATION OF AVERAGE BLOOD GLUCOSE 
Method 
Nathan et al. 
Equation 
eAG = (28.7 X A1C) - 46.7 
eAG (estimated average glucose) 
Reference 
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, 
Translating the A1C assay into estimated average glucose values. 
Diabetes Care 2008; 31 (8): 1473-8. 
ESTIMATION OF URINE PROTEIN TO CREATININE 
RATIO 
Technique 
Random Urine Collection 
Urine Creatinine in mg 
Urine Protein in mg 
Calculation of Urine Protein mg to Urine Creatinine mg ratio 
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Interpretation 
Normal ratio < 0.2gms protein / gm creatinine 
Reference 
Ruggenenti (1998) BMJ 316: 504. 
(2002) AM J Kidney Di 39: S1 
ESTIMATION OF UREA 
Technique 
Urea  (UV- GLDH) SLR – Assay 
Principle 
The test is performed as a 2 point kinetic assay in which the 
initial rate of the reaction is linear for a limited period of time. 
Urea in the sample is hydrolyzed by urease to ammonia and 
carbondioxide. The second reaction, catalyzed by the glutamate 
dehydrogenase converts ammonia and alpha-ketoglutarate to 
glutamate and water. Two moles of NADH are oxidized for each 
mole of urea present. 
The initial rate of decrease in absorbance at 340 nm is 
proportional to the urea concentration in the sample. 
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Sample Collection 
Serum is collected by standard procedure. Heparin is 
recommended as anticoagulation. 
Calculation 
∆A Sample  
---------------- x (50 Standard Concentration)  
∆A Standard  
= mg/dl urea in the sample. 
Reference Range 15-39mg/dl 
ESTIMATION OF CREATININE 
Technique 
Liquixx Creatinine (Modified Jaffe’s Method) 
Principle 
Creatinine reacts with alkaline picrate to produce orange- 
yellow colour (The Jaffe’s Reaction). Specificity of assay has been 
improved by the introduction of an initial rate method. 
The absorbance of the orange-yellow colour formed is 
directly proportional to creatinine concentration and is measured 
photometrically at 500-520nm. 
Sample 
Serum 
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Calculation 
∆ A of Test 
-------------------  x Concentration of Standard (mg/dl) 
∆ A of Standard 
= Creatinine mg/dl 
Reference Range 
Males 0.7 to 1.4mg/dl 
Females 0.6 to 1.2mg/dl 
FUNDUS PHOTOGRAPHY 
Fundus photography (also called fundography) is the creation 
of a photograph of the interior surface of the eye, including 
the retina, optic disc, macula, and posterior pole (i.e. thefundus).  
Fundus photography is used by optometrists, 
ophthalmologists, and trained medical professionals for monitoring 
progression of a disease, diagnosis of a disease (combined with 
retinal angiography), or in screening programs and epidemiology.  
Compared to ophthalmoscopy, fundus photography generally 
needs a considerably larger instrument, but has the advantage of 
availing the image to be examined by a specialist at another 
location and/or time, as well as providing photo documentation for 
future reference. Modern fundus photographs generally recreate 
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considerably larger areas of the fundus than what can be seen at any 
one time with handheld ophthalmoscopes. 
PROCEDURE 
Fundus photography is performed by post mydriatic test. 
Seven field stereo colour fundus photographic pictures of the 
patients were taken. The presence of microaneurysms, retinal 
haemorrhages (Dot and blot, retinal nerve fibre layer 
haemorrhages) hard exudates, cotton wool spots, venous beading 
and IRMA were identified. Presence of proliferative stage 
identified by neovascularization are excluded from the study. 
Grading of nonproliferative retinopathy into mild moderate and 
severe was done. Severe grade patients were excluded from the 
study. 
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STATISTICAL ANALYSIS 
Our study was a Cross-sectional study conducted among 100 
Type-II diabetic patients between 30-50 years of age. 
Two group were assigned according to the severity of 
Diabetic Retinopathy. One is a mild grade and another is a 
moderate grade. 
NIR, RDW and RBC count were analyzed in this study 
population. Also HBAIC and blood glucose levels were correlated 
with them. 
Statistical analysis was done with SPSS Software. Results 
were studied using unpaired t-test, chisquare test and Pearson 
coefficient Correlation.  
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34%
66%
DISTRIBUTION OF GENDER IN THE 
STUDY POPULATION
Male
Female
 
This diagram illustrates distribution of males and females among the study population. Female population 
comprises most of the study subjects with mild or moderate diabetic retinopathy. 
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45%
55%
DISTRIBUTION OF NPDR GRADES IN THE STUDY 
POPULATION
Mild
Moderate
 
This diagram illustrates the distribution of mild and moderate non proliferative diabetic retinopathy among 
the study population. Moderate non proliferative diabetic retinopathy constitutes 55% of the study group. 
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68
32
DISTRIBUTION OF BMI GRADES IN STUDY 
POPULATION
68
32
 
This diagram illustrates the distribution of body mass index among the study population. About 68% of the 
study subjects were the distributed in the over weight group. Only 32% of the patients constitute subjects with 
normal BMI. 
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This diagram illustrates the distribution of percentage of HBA1C among the study population. About 45% 
of the study population has HBA1C between 7% to 8%. Remaining group constitute poorly controlled glycemic 
status reflected by HBA1C more than 8%. 
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This diagram illustrates the distribution of Red Cell distribution with among subjects with mild and 
moderate non proliferative diabetic retinopathy. RDW is significantly increased in the moderate NPDR group. 
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PEARSON COEFFICIENT CORRELATION - COMPARING BMI AND HBA1C 
 
This diagram illustrates the pearson coefficient correlation between BMI and HBA1C 
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PEARSON COEFFICIENT CORRELATION - RDW AND ABG 
 
This diagram illustrates the pearson coefficient correlation between RDW and ABG 
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PEARSON COEFFICIENT CORRELATION - RDW AND HBA1C 
 
This diagram illustrates the pearson coefficient correlation between RDW and HBA1C 
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AGE 
Age  
Distribution 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 46 years 17 17.00 4 9.30 13 22.81 
47 to 48 years 36 36.00 12 27.91 24 42.11 
49 to 50 years 47 47.00 27 62.79 20 35.09 
Total 100 100 43 100 57 100 
 
Age Distribution Mild  NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 48.84 48.00 
SD 1.27 1.43 
P value Unpaired t test 0.2603 
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By conventional criteria the association between the study groups 
and age is considered to be not statistically significant since p > 0.05. 
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GENDER 
Gender  
Distribution 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
Male 34 34.00 9 20.93 25 43.86 
Female 66 66.00 34 79.07 32 56.14 
Total 100 100 43 100 57 100 
Chi-square value 5.74 
Degrees of freedom 1 
P value Chi Squared Test 0.1700 
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By conventional criteria the association between the study groups 
and gender is considered to be not statistically significant since p > 0.05. 
Since age and gender is not statistically significant, it means that 
there is no difference between the groups. In other words the groups 
contain subjects with the same basic demographic characteristics. 
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BMI 
BMI  
Distribution 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
18.50 to 24.99  
(Normal) 70 70.00 36 83.72 34 59.65 
25 to 29.99  
(Overweight) 30 30.00 7 16.28 23 40.35 
≥ 30 (Obese) 0 0.00 0 0.00 0 0.00 
Total 100 100 43 100 57 100 
 
BMI Distribution Mild NPDR Moderate NPDR 
N 43 57 
MEAN 22.75 24.55 
SD 1.87 2.86 
P value Unpaired t test 0.0002 
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By conventional criteria the association between the study 
groups and BMI among study subjects is considered to be 
statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR in persons with increased BMI 
among our study subjects.  In short progression of NDPR increases 
significantly with higher BMI. 
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DURATION OF DIABETES 
Duration of  
Diabetes 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 5 years 0 0.00 0 0.00 0 0.00 
6 to 10 years 83 83.00 39 90.70 44 77.19 
10 to 15 years 17 17.00 4 9.30 13 22.81 
Total 100 100 43 100 57 100 
 
Duration of Diabetes Mild  NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 9.01 9.18 
SD 1.08 1.59 
P value Unpaired t test 0.5408 
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By conventional criteria the association between the study 
groups and duration of diabetes among study subjects is considered 
to be statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR in persons with increased duration 
of diabetes among our study subjects.  In short progression of 
NDPR increases significantly with higher duration of diabetes. 
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RED CELL DISTRIBUTION WIDTH 
Red Cell  
Distribution  
Width 
All  
patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
< 11.6 % 0 0.00 0 0.00 0 0.00 
11.6 to 14 % 8 8.00 8 18.60 0 0.00 
> 14 % 92 92.00 35 81.40 57 100.00 
Total 100 100 43 100 57 100 
 
Red Cell  
Distribution Width 
Mild  
NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 14.14 15.44 
SD 0.70 0.72 
P value Unpaired t test 0.0000 
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By conventional criteria the association between the study 
groups and red cell distribution width among study subjects is 
considered to be statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR  in persons with increased and red 
cell distribution width levels among our study subjects.  In short the 
value of and red cell distribution width shows significantly 
increasing trend as severity of diabetic retinopathy increases. 
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NEUTROPHIL: LYMPHOCYTE RATIO 
Neutrophil :  
Lymphocyte  
ratio 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
< 2 43 43.00 37 86.05 6 10.53 
>2 57 57.00 6 13.95 51 89.47 
Total 100 100 43 100 57 100 
 
Neutrophil :  
Lymphocyte ratio Mild NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 1.62 2.27 
SD 0.34 0.44 
P value Unpaired t test 0.0000 
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By conventional criteria the association between the study 
groups and neutrophil lymphocyte ratio among study subjects is 
considered to be statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR  in persons with increased 
neutrophil lymphocyte ratio levels among our study subjects.  In 
short the value of neutrophil lymphocyte ratio shows significantly 
increasing trend as severity of diabetic retinopathy increases.  
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HBA1C 
HBA1c  
Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 7%  
(Good Control) 1 1.00 1 2.33 0 0.00 
7.1 to 8%  
(Fair Control) 44 44.00 22 51.16 22 38.60 
> 8%  
(Poor Control) 55 55.00 20 46.51 35 61.40 
Total 100 100 43 100 57 100 
 
HBA1c Levels Mild NPDR Moderate NPDR 
N 43 57 
MEAN 8.69 9.72 
SD 1.62 2.00 
P value Unpaired t test 0.0052 
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By conventional criteria the association between the study 
groups and Blood HBA1c levels among study subjects is considered 
to be statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR  in persons with increased HBA1c 
levels among our study subjects.  In short the value of glycosylated 
haemoglobin shows significantly increasing trend as severity of 
diabetic retinopathy increases. 
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ABG 
Average  
Blood Glucose  
Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 200 mg/dl  
(Good Control) 
53 53.00 30 69.77 23 40.35 
> 200 mg/dl 
 (Poor Control) 
47 47.00 13 30.23 34 59.65 
Total 100 100 43 100 57 100 
 
Average Blood Glucose Levels Mild  NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 202.59 232.24 
SD 46.38 57.29 
P value Unpaired t test 0.0052 
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By conventional criteria the association between the study 
groups and average blood glucose levels among study subjects is 
considered to be statistically significant since p < 0.05. 
We conclude that there is meaningfully real increase in risk 
of developing moderate NDPR  in persons with increased average 
blood glucose levels among our study subjects.  In short the value 
of average blood glucose shows significantly increasing trend as 
severity of diabetic retinopathy increases. 
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RBC COUNT 
RBC  
Count 
All  
Patients % 
Mild  
NPDR % 
Moderate 
NPDR % 
< 3.8  
million/cumm 0 0.00 0 0.00 0 0.00 
3.6 To 5.9  
million/cumm 100 100.00 43 100.00 57 100.00 
Total 100 100 43 100 57 100 
 
RBC Count Mild NPDR Moderate NPDR 
N 43 57 
MEAN 4.65 4.80 
SD 0.29 0.30 
P value Unpaired t test 0.0143 
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The RBC count levels in mild NDPR group is meaningfully 
less than moderate NDPR group by 1.12 times with a mean 
difference of 0.55 million/cu mm. This difference is true and 
significant and has not occurred by chance. 
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HAEMOGLOBIN 
Haemoglobin  
Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
< 12 gm/dl 16 16.00 5 11.63 11 19.30 
12 to 14 gm/dl 76 76.00 38 88.37 38 66.67 
> 14 gm/dl 8 8.00 0 0.00 8 14.04 
Total 100 100 43 100 57 100 
 
Haemoglobin Levels Mild NPDR Moderate NPDR 
N 43 57 
MEAN 13.00 12.94 
SD 0.64 0.92 
P value Unpaired t test 0.7203 
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By conventional criteria the association between the study 
groups and Haemoglobin status is considered to be not statistically 
significant since p > 0.05. 
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UREA 
Blood Urea  
Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 40 mg/dl 100 100.00 43 100.00 57 100.00 
> 40 mg/dl 0 0.00 0 0.00 0 0.00 
Total 100 100 43 100 57 100 
 
Blood Urea Levels Mild NPDR Moderate NPDR 
N 43 57 
MEAN 26.65 27.72 
SD 3.52 3.24 
P value Unpaired t test 0.1236 
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By conventional criteria the association between the study 
groups and blood urea status is considered to be not statistically 
significant since p > 0.05. 
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CREATININE  
Serum  
Creatinine  
Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
< 0.8 mg/dl 54 54.00 22 51.16 32 56.14 
0.8 to 1.2 mg/dl 46 46.00 21 48.84 25 43.86 
Total 100 100 43 100 57 100 
 
Serum Creatinine Levels Mild NPDR Moderate NPDR 
N 43 57 
MEAN 0.66 0.65 
SD 0.18 0.15 
P value Unpaired t test 0.8206 
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By conventional criteria the association between the study 
groups and serum creatinine status is considered to be not 
statistically significant since p > 0.05. 
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U.SPOT PCR 
U.SPOT  
PCR Levels 
All  
Patients % 
Mild  
NPDR % 
Moderate  
NPDR % 
≤ 0.2 g prote  
in/day 100 100.00 43 100.00 57 100.00 
> 0.2 g prote  
in/day 0 0.00 0 0.00 0 0.00 
Total 100 100 43 100 57 100 
 
U.SPOT  
PCR Levels 
Mild  
NPDR 
Moderate  
NPDR 
N 43 57 
MEAN 0.12 0.12 
SD 0.03 0.03 
P value Unpaired t test 0.9951 
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By conventional criteria the association between the study 
groups and U Spot PCR is considered to be not statistically 
significant since p > 0.05. 
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DISCUSSION 
Diabetic Retinopathy is a major cause of blindness among 
diabetic patients. It is the sixth common cause of blindness in India. 
Prevalence of Diabetic retinopathy in patients with diabetes was 
recently estimated to be 34.6%. 
Ocular fundus examination every year by an ophthalmoscope 
is the most important clinical assessment in a diabetic patient to 
detect diabetic retinopathy. But accessibility and awareness to 
undergo such an examination is lacking both in the diabetic 
population and among the medical practitioners. 
Many pathophysiological disorders and mechanisms have 
been proposed for the development and progression of diabetic 
retinopathy but the most common are Rheological disorders2 of red 
blood cells and RBC deformability. 
Recently vascular inflammation in proposed as the basic 
pathogenic mechanism behind microvascular complications and 
hence detection of markers for vascular inflammation4 can help us 
to diagnose diabetic microangiopathy particularly diabetic 
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retinopathy very early, so that active intervention in that stage 
would prevent a diabetic patient from becoming blind. 
Since rheological disorders of RBCS play a pivotal sole in the 
pathogenesis of diabetic retinopathy, red cell distribution width4  
(a measure of variation in size and volume of RBCS) can be a 
useful marker for the detection of Diabetic Retinopathy.  
Also the basis for such rheological disorders of RBCS leading 
to the development of NPDR is recently proposed as vascular 
inflammation, we tried to prove the markers of vascular 
inflammation also gets elevated in parallel to RDW during the 
progression of disease in NPDR. There are many number of 
inflammatory markers available, but Neutrophil– lymphocyte ratio5 
appears to be more significant.  
Numerous studies5 are available in literature for the 
correlation of NLR and vascular inflammation. Hence NLR in the 
early detection of NPDR appears to be the best predictor of 
progression of disease in DR.   
In our study, (Cross sectionally designed observational study) 
we selected 100 Type-II diabetic patients with features of mild or 
moderate stages of diabetic retinopathy. No excluded severe NPDR 
 103 
and proliferate DR because numerous studies have shown that a 
degree of erythropoietin resistance and albuminuria heralds the 
onset of proliferative DR. Also we excluded anaemia3 from the 
study because of its interference with RDW and sometimes 
clinically undetectable erythropoietin resistance from early CKD 
can present leading to anaemia. 
In our study, we found significant elevation of RDW6 among 
subjects with mild and moderate NPDR. The elevation was 
significant in the moderates NPDR group. Statistically p value was 
found to be highly significant. Pearson coefficient correlation was 
found to be 0.465 when compared with HBA1C. 
In the moderate NPDR group RDW elevation also parallels 
the HBA1C and average blood glucose values. All these subjects 
belonging to the moderate NPDR group had uncontrolled blood 
glucose levels and elevated HBA1C levels.  
Neutrophil Lymphocyte Ratio5 was also found to be 
significantly elevated among our subjects particularly in moderate 
NPDR group. Statistically p value was found to be very significant. 
These subjects also had elevation of HBA1C and blood glucose 
levels in parallel with the elevation of NLR. Pearson coefficient 
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correlation in comparing the NLR with HBA1C values was found to 
be significant.  
RBC count is not significantly decreased in any of the 
subjects of our group.  There is also no significant correlation with 
RDW and NLR. 
All subject had normal urea and creatinine levels without any 
evidence of albuminuria.  
Haemoglobin values were of normal levels and had no 
significant correlation with any of the parameter in our study. 
HBA1C was elevated particularly among the moderate NPDR 
group and had significant correlation with the severity of disease 
and also duration of diabetes. 
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SUMMARY AND CONCLUSION 
SUMMARY 
A study an establishing the role of RDW, NLR and RBC 
count as markers for the early detection of mild and moderate 
NPDR was conducted. 
A total of 100 subjects meeting the inclusion and exclusion 
criteria were selected. 
After a thorough clinical examination, fundus examination 
and blood sampling was done. 
All results were analyzed by SPSS software and derivation 
were done by unpaired t test, chi-square test and Pearson 
coefficient correlation.  
After analysis we found that both mild and moderate NPDR 
group of patients had significant elevation of RDW and NLR. 
Hence RDW and NLR can be potential markers for early 
detection of mild and moderate NPDR.  
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CONCLUSION 
Diabetic Retinopathy is a major concern among diabetic 
patients because failure to detect it early and failure to prevent the 
progression of disease leads to blindness in 90% of diseased 
population. Only expertise in fundus photography could be able to 
detect NPDR and PDR in diabetic patients.  
Taking into account the huge diabetic population and the scarce 
availability of such experts, it will be difficult to screen & diagnose 
the entire diabetic population which is enlarging it an exponential 
manner yearly. Hence in the search for markers to defect early DR 
even at the primary care physician level, we took the opportunity to 
correlate RDW and NLR with different grades of NIDR.  
From our study we conclude that, both NLR and RDW are 
useful markers of vascular inflammation for  
1) Early diagnosis of Non-proliferative diabetic retinopathy. 
2) Assessing the severity of non protiferative Diabetic 
Retinopathy as mild or moderate grades.  
3) Also their prediction of uncontrolled glycaemic status since 
they correlate well with HBA1C and blood glucose levels.  
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LIMITATIONS OF OUR STUDY 
Our study correlated RDW and NLR with vascular 
inflammation in Diabetic patients. Further diagnostic indices like 
Doppler study of carotid and peripheral vessels for identifying 
carotid intima medial thickness sand peripheral atherosclerotic 
vascular disease could have been done for correlation. But many 
factors like time and economy led to a limitation of evaluation of 
certain factors in our study. 
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SCOPE FOR FURTHER STUDY 
FUTURE PROSPECTS OF THE STUDY 
RDW and NLR are now both physiologically and 
pathologically established diagnostic indices of vascular disease 
particularly in diabetic population. Hence apart from their ability in 
diagnosing NPDR both can be used for certain other scenarios like 
1) RDW and NLR can be used to diagnose diabetic 
macrovascular disease. 
2) RDW and NLR can be used to diagnose and monitor diabetic 
foot complications. 
3) RDW and NLR can be used to define the glycemic status 
apart from HBA1C levels. 
 
 
 110 
BIBLIOGRAPHY 
1) Javitt JC, Canner JK, Frank RG et al, Detecting and treating 
retinopathy in patients with type I diabetes mellitus. 
Ophthalmology 1990:97:483 - 494. 
2) The Diabetes Control and Complications Trial Research 
Group: The effect of intensive treatment of diabetes on the 
development and progression of long-term complications in 
insulin-dependent diabetes mellitus. N Engl J Me 
1993:329:977-986. 
3) Malone JI, Morrison AD, Pavan PR, Cuthbertson DO: 
Prevalence and significance of retinopathy in subjects with 
type 1 diabetes of less than 5 years’ duration screened for the 
Diabetes Control and Complications Trial. Diabetes care 
200124:522 - 526. 
4) Klein ft Klein BE: Vision disorders in diabetes. In Harris, Ml. 
Hammari, RF (eds): Diabetes in America (DHHS publication 
number 85-1468). Washington, DC, United States 
Government Printing Office, 1985, p1. 
 111 
5) Klein R, Klein BE, Moss SE, Cruickshanks KJ: Association 
of ocular disease and mortality in a diabetic population. Arch 
Ophthalmology 1999;117:1487-1495. 
6) Klein R, Klein B, Moss S, at The Wisconsin epidemiologic 
study of diabetic retinopathy. XIV. Ten-year Incidence and 
progression of diabetic retinopathy. Arch Ophthalmol 1994 ; 
112: 1217-1228, 
7) Roserin B, Miodovnik M, Kranias G, et al: Progression of 
diabetic retinopathy in pregnancy: Association with 
hypertension in pregnancy. Am J Obstet Gynecol 
1992:166:1214-1218. 
8) Frank RN: On the pathogenesis of diabetic retinopathy: A 
1990 update. Ophthalmology 1991:98:586-593. 
9) Frank RN: The aldose reductase controversy. Diabetes 
1994:43:169-172. 
10) Peterson CA, Delamere NA: The lens. In Hart WM (ed): 
Adler’s Physiology of the Eye. 2nd ed. St Louis, Mosby-Vear 
Book, 1992, pp 361-381. 
 112 
11) Vlassara H: Protein glycation in the kidney: Role in diabetes 
and aging. Kidney Int 1996;49:1795-1 804. 
12) Brownlee M: Glycation and diabetic complications. Lilly 
Lecture 1993. Diabetes 1994:43:836-841. 
13) Makita Z, Radoff S, Raytield EJ, etal: Advanced 
glycosylation end products in patients with diabetic 
nephropathy. N Engi J Med 1991:325:836-842. 
14) Pierce E, Foley E, Smith L: Regulation of vascular 
endothelial growth factor by oxygen in a model of retinopathy 
of prematurity. Ophthalmology 1996:114:1219-1228. 
15) Aiello L, Avery R, Arrigg P, at at: Vascular endothelial 
growth factor in ocular fluid of patients with diabetic 
retinopathy and other retinal disorders. N Engi J Med 
1994;331 :1480-1487. 
16) Adamis A, Shima D, Tolentino M, at al: Inhibition of VEGF 
prevents retinal ischemia associated iris neovascularization in 
non-human primate. Arch Ophthalmol 1996:114:66-71. 
17) Eyetech Pharmaceuticals: http:// www. eyetk. comlctinicall 
clinical_index.asp. 
 113 
18) Heier JS, Sy JR McCluskey E: RhuFabV2 (anti-VEGF 
antibody) for treatment of exudative AMD. Program and 
abstracts of the American Academy of Ophthalmology 2002 
Annual Meeting, Orlando. Fla, October 20-23, 2002. 
19) Slakter J, Singerman L, Yanuzzi L, at al: Anecortave acetate 
administered as posterior juxtascleral injection in patients 
with subfoveal choroidal neovascularization. Program and 
abstracts of the American Academy of Ophthalmology 2002 
Annual Meeting, Orlando, Fla, October 20-23, 2002. 
20) Early Treatment Diabetic Retinopathy Study Research Group: 
Fundus photographic risk factors for progression of diabetic 
retinopathy. ETDRS Report No. 12. Ophthalmology 
199198:823-833. 
21) Early Treatment Diabetic Retinopathy Study Research Group: 
Early photocoagulation for diabetic retinopathy. ETDRS 
Report No, 9. Ophthalmology 1991:98: 766-785. 
22) Gaas JDM: Stereoscopic Atlas of Macular Diseases: 
Diagnosis and Treatment, 4th ad. St Louis, Mosby, 1997, p4. 
 114 
23) Rho DS: Treatment of acute pseudophakic cystoid macular 
edema: Diclofenac versus ketorolac. J Cataract Refract Surg 
2003:29:2378-2384. 
24) Massin P. Audren F, Haouchine B, at al., Intravitreal 
triamcinolone acetonide for diabetic diffuse macular edema: 
Preliminary results of a prospective controlled trial. 
Ophthalmology 2004:111:218-224. 
25) Mmomi M. Satoh M: Chemokines end their receptors in the 
brain: Pathophysiological role, In Ischemic brain injury. Life 
Sal 74:3l-327 
26) Schwartz D: Corneal sensitivity in diabetics. Arch 
Ophthalmol, 1974:91:174-178. 
27) Klein B, Klein R, Jensen S: Open-angle glaucoma and older 
onset diabetes: the Beaver Dam Eye Study. Ophthalmology 
1994:101:1173-1177. 
28) Jacobson 0, Murphy R, Rosenthal A: The treatment of angle 
neovascularization with panretinal photocoagulation. 
Ophthalmology 1979:86:1270-1275. 
 115 
29) Bernth-Peterson P. Bach E: Epidemiologic aspects of cataract 
surgery. Ill: Frequencies of diabetes and glaucoma in a 
cataract population. Acta Ophthalmol 1983:61:406-416. 
30) Krupsky 5, Zalish M, Oliver M, et al: Anterior segment 
complications in diabetic patients following extracapsular 
cataract extraction and posterior chamber intraocular lens 
implantation. Ophthalmic Surg 1991 22:526-530. 
31) Hykin P, Gregson R, Stevens J, at al: Extracapsular cataract 
extraction in proliferative diabetic retinopathy. 
Ophthalmology 1993:100:394-399. 
32) Regillo C, Brown G, Savino P. at al: Diabetic papillopathy: 
Patient characteristics and fundus findings. Arch Ophthalmol 
1995:113:889-895. 
33) Burde A: Neuro-ophthalmic associations and complications of 
diabetes mellitus. Am J Ophthalmol 1992:114:498—501. 
34) American Diabetes Association: Position statement: Diabetic 
retinopathy. Diabetes Care 2001 :24 (Suppl):S73. 
35) American College of Physicians, American Diabetes 
Association. American Academy of Ophthalmology: 
 116 
Screening guidelines for diabetic retinopathy. Clinical 
Guideline. Ophthalmology 1992:99:1626-1627. 
36) Moss SE, Klein R, Kessler SD, Richie KA: Comparison 
between ophthalmoscopy and fundus photography in 
determining severity of diabetic retinopathy. Ophthalmology 
1985:92:62-67. 
37) Chew E, Klein M, Murphy R. at al: Effects of aspirin on 
vitreousl preretinal hemorrhage in patients with diabetes 
mellitus. ETDRS Report No. 20. Arch Ophthalmol 
1995:113:52-55. 
38) Diabetic Retinopathy Study Research Group: Four risk 
factors for severe visual loss in diabetic retinopathy: The 
third report from the Diabetic Retinopathy Study. Arch 
Ophthalmol 1979:97:654-665. 
39) Lewis H, Abrams G, Blumenkranz M, at at: Vitrectomy for 
diabetic macular traction and edema associated with posterior 
hyaloidal traction. Ophthalmology 1 992; 99: 753-759. 
40) Diabetic Retinopathy Vitrectomy Study Research Group: 
Early vitrectomy for severe proliferative diabetic retinopathy 
in eyes with useful vision. results of a randomized trial - 
 117 
Diabetic Retinopathy Vitrectomy Study Report 3. 
Ophthalmology 198895:1307-120. 
41) Ferris F: How effective are treatments for diabetic 
retinopathy? JAMA 1993:269:1290-1291. 
42) Javltt JC, Aieilo LP, Chiang Y. at al., Preventive eye cure in 
people with diabetes is cost saving to the federal government. 
Implications for health-care reform, Diabetes Care 
1994:17:909-917. 
43) Pollreiszand A, Schmidt-Erfurth U. Diabetic Cataract—
Pathogenesis. Epidemiology and Treatment. Journal of 
Ophthalmology. 2010 
44) Melendez-Ramirez LY, Richards RJ, Cefalu WT. 
Complications of Type 1 diabetes. Endocrino/ Metab C/in 
North Am. 201 O;39(3l :625-40 
45) Kumar A. Diabetic blindness in India: The emerging scenario. 
Indian J Ophthamol, 1998;46:65-6. 
46) Shah SP. Non-Retinal Complications of Diabetes Mellitus. 
Williams H, Airey M, Baxter H, Forrester J, Kennedy-Martin 
 118 
T, Girach A. Epidemiology of diabetic retinopathy and 
macular oedema: a systematic review. Eye. 2004;18 :963—83 
47) Brownlee M, Aiello LP, Cooper ME, Vinik Al, Nesto RW, 
Boulton AJM. Chapter 32 - Complications of Diabetes 
Mellitus. In: Kronenberg. 
48) HM, et al Leds. L. Williams Textbook of Endocrinology, 11th 
edition; 2008. Saunders Elsevier: Philadelphia: 1417-43. 
49) Klein R, Klein BEK, Moss SE. Relation of Glycemic Control 
to Diabetic Microvascular Complications in Diabetes 
Mellitus. Annals of Internal Medicine.1996;124(1)2:90-6 
50) Cheung N, Mitchell P, Wong TV. Diabetic retinopathy. 
Lancet 2010; 376: 124-36. 
51) Cavallerano J. Care of the patient with diabetes mellitus. 
American Optometric Association. 2009. 
52) Rema M, Pradeepa R. Diabetic retinopathy: An Indian 
perspective. Indian J Med Res2007;125:297-310 
53) Negi A, Vernon SA. An overview of the eye in diabetes. J R 
Soc Med. 2003; 96(6): 266-72 
 119 
54) Steinle NC, Ambati J. Retinal Vasculopathies: Diabetic 
Retinopathy. 2010 Elsevier Ltd 
55) Rema M, Premkumar S, Anitha B,et al. Prevalence of diabetic 
retinopathy in urban India: The Chennai Urban Rural 
Epidemiology Study (CURES Eye Study. I. Invest 
Ophthalmol VII Sci 2005; 46:2328-33 
56) Rosenblatt BJ, Benson WE. Chapter 6.19 -Diabetic 
Retinopathy. In: Yanoff M, et aI (eds.). Yanoff & Duker: 
Ophthalmology; 3rd edition, 2008. Saunders Elseviers. 
57) Ciulla TA, Amador AG, Zinman B. Diabetic Retinopathy and 
Diabetic Macular Edema: Pathophysiology, screening, and 
novel therapies. Diabetes Care. 2003;26(9): 265 3-64 
58) Bhavsar AR. Retinopathy, Diabetic, Proliferative. eMdicine. 
Last updated Oct  6 2009  
59) Toole L. Features of Diabetic Retinopathy ar4 Grading 
Protocols.  
60) Sjolie A. Retinal Photography and the assessment of Diabetic 
Retinopathy In the DIRECT Proramme. The Diabetic 
RtIriopethy Candasartan Triala. 
 120 
61) Wilkinson CP. Classification of Diabetic Retinopathy: A 
Proposed International Clinical Disease Severity Grading 
Scale for Diabetic Retinopathy and Diabetic Macular Edema. 
Medscape. 2004. 
62) Diabetic Retinopathy. American Academy of Ophthalmology. 
2008. 
63) Wilkinson CP, Ferris FL, Klein RE, Lee PP. Agardh CD, 
Davis M, et al., Proposed International Clinical Diabetic 
Retinopathy and Diabetic Macular Edema Disease Severity 
Scales. Ophthalmology 2003; 1 10:1677-82 
64) Sjolie A. Progression to retinopathy. The Diabetic 
Retinopathy Candesartan. 
65) Trials -Stewart JM, Schwartz DM. Retinopathy. In: Goldfine 
ID, Rushakoff RJ. Endotext 
66) Diabetic Retinopathy. Evidence-Based Physical Diagnosis 
(Second Edition), 2007, 234-41 
67) Newsom R. Screening for diabetic retinopathy. Diabetic Eye 
Disease. 2000: 90-9 
 121 
68) Jawa A, Kcom J, Fonseca VA. Diabetic nephropathy and 
retinopathy. Medical Clinics of North America. 2004;88(4): 
1001-36 
69) Management of diabetic retinopathy and diabetic 
maculopathy - laser, surgical and medical approaches. 
Diabetes and the Eye. 2008:99-165 
70) Massin P, Paques M, Pournaras J. Diabetic macular edema. 
Ocular Disease. 2010:519-26 
71) Bhagat N, Grigorian RA, Tutela A,et at. Diabetic Macular 
Edema: Pathogenesis and Treatment. Survey of 
Ophthalmology 2009; 54 11:1-32. 
72) lnzucchi SE, Sherwin RS. Chapter 247 - Type 1 Diabetes 
Mellitus. Goldman: Cecil Medicine, 2007; 23rd edition. 
73) Jeganathan SVE, Wang JJ, Wong TY. Ocular Associations of 
Diabetes Other Than Diabetic Retinopathy. Diabetes Care. 
2008;3 1(91:1905-12 
74) Kador PF. Diabetes-associated cataracts. Ocular Disease. 
2010:243-9 
 122 
75) Javadi M, Zarei-Ghanavati S. Cataracts in Diabetic Patients: 
A Review Article. J Ophthalmic Vis Res 2008; 3(1): 52-65 
76) EKanner ME, Netiand PA. Chapter216 - Glaucoma associated 
with disorders of the retina, vitreous, and choroid. In: Albert 
& Jakobiec’s Principles & Practice of Ophthalmology, 3rd ed. 
2008: Saunders Elseviers. Tumosa N. Eye Disease and the 
Older Diabetic. Cl/n Geriatr Med 2008; 24: 5 15-27 
77) Klig JE. Ophthalmologic Complications of Systemic Disease. 
Emerg Med C/in N Am 2008; 26: 217-31. 
 133 
MICROANEURYSMS (HYPERFLUORESCENT DOTS),  
DOT BLOT HAEMORRHAGES (DARK SPOTS) 
 
 
 
MACULAR EDEMA WITH HARD EXUDATES 
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FUNDUS IMAGES OF COTTON WOOL SPOTS 
 
 
FUNDUS IMAGES OF VENOUS BEADING 
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FUNDUS IMAGES OF IRMA 
 
 
FUNDUS IMAGES OF NEOVASCULARIZATION 
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RED BLOOD CELL - 3D IMAGE 
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Determination of RDW-SD measurement.  
In this example, RDW-SD is 38.2 fL. 
 
 
 
Calculation of RDW-CV measurement, which is derived from 1SD 
divided by MCV times 100%. In this example, RDW-CV is 12.8%.
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ORGANIZATION OF THE ERYTHROCYTE MEMBRANE 
 
PROFORMA 
Name:     Age:   Sex: 
Address:       Ph.No: 
 
Occupation:   Income:  Religion: 
Duration of Diabetes: 
Preventing Complaints: Pertinent to Vision 
PAST MEDICAL HISTORY 
Hypertension/ IHD/ Stroke/ Trauma/ Recent Surgeries 
Drug Intake: 
Family History:   DM/HT/IHD 
Personal History: Diet, Veg/ Non Veg 
Smoking: Average No. of beedies/ Cigarates/ Day / Year 
Alcohol: Quantity consumed/ day x Duration in Years 
GENERAL EXAMINATION 
Built and Nourishment 
Height in cm:   Weight in Kgs:  BMI in Kg/m2: 
Pallor/ cyanosis/ Clubbing/ Edema/ Jaundice/ Lymphadenopathy 
VITAL PARAMETERS 
Pulse:    BP: 
SYSTEMIC EXAMINATION 
CVS:   RS:    P/A:   CNS: 
FUNDUS EXAMINATION 
Micro Aneurysms 
Hard Exudates 
Haemorrhages 
Phlebopathies 
INVESTIGATIONS 
Blood 
Hb% 
PCV 
RBC Count 
RDW 
WBC Count 
Differential Count:   N: L: E: M: 
MCV:   MCH:   MCHC 
PLT Count:    PDW: 
ESR: 
ABG:   HBA1C: 
Urea:   Creatinine:  
Urine Spot PCR 

GOVT. STANLEY MEDICAL COLLEGE,  
CHENNAI – 600001 
INFORMED CONSENT 
A study on Red cell Distribution width, Red Blood Cell count 
and Neutrophil/ Lymphocyte Ratio as Potential Markers of 
Vascular Inflammation in the Early Detection of Microvascular 
Complications Particularly Diabetic Retinopathy in patients with 
Diabetes Attending Government Stanley Hospital, Chennai. 
Place of study:  Govt. Stanley Medical College, Chennai 
I ……………………………………………. have been informed 
about the details of the study in my own language. 
 I have completely understood the details of the study. 
 I am aware of the possible risks and benefits, while taking 
part in the study. 
 I understand that I can withdraw from the study at any 
point of time and even then, I can receive the medical 
treatment as usual. 
 I understand that I will not get any money for taking part in 
the study. 
 I will not object if the results of this study are getting 
published in any medical journal, provided my personal 
identity is not revealed. 
 I know what I am supposed to do by taking part in this 
study and I assure that I would extend my full cooperation 
for this study.   
 
Volunteer: 
Name and address 
Signature/thumb impression 
Date 
Witness: 
Name and address Signature/thumb 
impression 
Date 
 
Investigator  
Signature and date 
muR °lh‹È kU¤Jt¡ fšÿÇ, br‹id-600 001. 
A study on Red cell Distribution width, Red Blood Cell count 
and Neutrophil/ Lymphocyte Ratio as Potential Markers of 
Vascular Inflammation in the Early Detection of Microvascular 
Complications Particularly Diabetic Retinopathy in patients with 
Diabetes Attending Government Stanley Hospital, Chennai. 
eh‹ ïªj MuhŒ¢áÆ‹ Étu§fis K‰¿Y« òÇªJbfh©nl‹. 
MŒÉš g§F vL¤jnghJ, rh¤âakhd mgha§fŸ k‰W« 
ga‹fis g‰¿ eh‹ m¿ªJŸns‹. 
eh‹ vªjbthU ntisÆY« MŒÉš ïUªJ âU«g Koí«, 
mj‹ ã‹d®, eh‹ tH¡f«nghš kU¤Jt á»¢ir bgw Koí« v‹W 
òÇªJbfhŸ»nw‹. 
eh‹ MŒÉš g§F vL¤J gz« vijí« bgw KoahJ v‹W 
m¿ªJŸns‹. 
ïªj MŒÉ‹ KoîfŸ vªj bko¡fš #®dÈš btËÆl¥gl 
ïUªjhš mij eh‹ vâ®¡fÉšiy, v‹ jÅ¥g£l milahs¤ij 
btË¥gL¤j¥g£L ïU¡f¡ TlhJ.  
eh‹ ïªj MŒÉš g§bfL¥gj‹ _y« eh‹ v‹d brŒa¥ 
ngh»nw‹ v‹W bjÇí«. eh‹ ïªj MŒÉš v‹ KG x¤JiH¥igí« 
bfhL¥ng‹ v‹W cWâaË¡»nw‹. 
 
 
j‹dh®ts® rh£á 
bga® k‰W« KftÇ bga® k‰W« KftÇ 
ifbah¥g«/ Éuš nuif ifbah¥g«/ Éuš nuif 
 
MuhŒ¢áahsuhf 
ifbah¥g« k‰W« njâ 
SL.NO Age SEX BMI D-DIABET HB HBA1C ABG UREA CREAT U.SPOT PCR RBC COUNT N/L RDW NPDR- GR
1 50 F 21.1 8 11.8 7.4 165.68 28 0.8 0.12 4.41 1.85 15.6 MILD
2 50 F 27.3 11 13.5 8.2 188.64 29 0.8 0.11 4.77 1.29 14.2 MILD
3 50 F 26.1 10 13.2 12.6 314.92 27 0.8 0.14 4.88 1.41 14.5 MILD
4 48 F 24 12 11.6 10.6 257.52 27 0.8 0.12 4.84 1.98 15.1 MOD
5 48 M 27.6 10 14.9 7.5 168.55 30 0.6 0.08 5.55 3.16 14.9 MOD
6 46 M 29 11 13.5 13.4 337.88 32 0.8 0.13 5.03 2.16 15.1 MOD
7 48 F 27.2 12 11.8 7.9 180.03 28 0.6 0.09 4.73 1.13 17.4 MOD
8 50 F 24 8 13.7 7.8 177.16 30 0.9 0.12 4.96 1.54 12.2 MILD
9 49 F 23.2 9 11.8 8.1 185.77 29 0.9 0.14 4.03 2.23 12.4 MILD
10 49 F 21.6 8 12.7 7.9 180.03 30 0.6 0.09 4.69 1.58 14.5 MOD
11 50 F 22.3 10 13.9 8 182.9 34 0.6 0.16 5.05 1.39 13.8 MILD
12 48 F 21.9 8 12.9 9.6 228.82 22 0.8 0.08 4.63 2.15 14.3 MILD
13 50 F 21 8 11.9 12.2 303.44 30 0.5 0.09 4.56 2.73 14.4 MOD
14 46 F 23.1 8.5 13.5 9.1 214.47 21 0.6 0.12 4.42 1.4 14.1 MILD
15 48 M 21.3 8 13.2 7.6 171.42 26 0.5 0.11 4.41 1.8 14.2 MILD
16 47 F 22.6 6.5 11.9 10.5 254.65 23 0.6 0.14 4.63 1.98 14.5 MOD
17 46 M 29 11 13.5 13.4 337.88 32 0.8 0.13 5.03 2.16 15.1 MOD
18 50 F 27.1 10 12 8 182.9 28 0.8 0.09 4.42 2.1 15.5 MOD
19 48 F 22 8 12.4 9.1 214.47 26 0.3 0.12 4.71 2.6 15.3 MOD
20 46 M 21.6 8.5 14.1 8 182.9 28 0.6 0.16 5.2 2.9 14.8 MOD
21 48 M 25.1 8 13.2 10.6 257.52 32 0.8 0.14 4.5 2.42 15.8 MOD
22 50 F 21.3 9 12.2 7.8 177.16 26 0.6 0.08 4.71 1.29 13.2 MILD
23 49 F 21 8.5 13.5 7 154.2 25 0.2 0.11 4.96 1.24 14.1 MILD
24 46 F 21.3 8 12.9 7.6 171.42 22 0.6 0.09 4.41 1.8 14.2 MILD
25 46 M 21.6 8.5 14.1 8 182.9 28 0.6 0.16 5.1 2 14.8 MOD
26 50 F 25.1 10 13.9 12.2 303.44 26 0.5 0.09 4.54 2.8 15.8 MOD
27 48 F 27.2 12 12.8 7.6 171.42 28 0.6 0.12 4.73 2.1 17.4 MOD
28 50 F 24 10 13.2 11 269 27 0.8 0.11 4.88 1.41 14.5 MILD
29 46 M 29 8 13.5 13 326.4 32 0.8 0.14 5.03 2.26 16 MOD
30 49 F 21.6 8 12.7 7.9 180.03 30 0.8 0.13 4.68 1.64 15.2 MOD
31 50 F 21 8.5 12 9.4 223.08 28 0.8 0.12 4.54 2.72 15.4 MOD
32 50 M 25.2 12 13.2 11.6 286.22 32 0.8 0.14 4.52 2.8 14.5 MILD
33 49 F 21.1 8 12.7 7.8 177.16 26 0.2 0.09 5.05 1.39 14.2 MILD
34 50 F 24 8.5 13.1 8.6 200.12 24 0.4 0.16 4.54 2.26 16.2 MOD
35 47 F 24.6 6.5 12.3 10.5 254.65 28 0.4 0.08 4.64 1.98 15.6 MOD
36 49 F 23.1 9 12.1 7.8 177.16 30 0.8 0.09 4.94 1.4 14.6 MILD
37 48 M 21.4 8 13.8 8 182.9 26 0.4 0.12 4.42 1.62 14.2 MILD
38 50 M 23.4 10 13.2 8.2 188.64 30 0.8 0.11 4.68 1.46 14.1 MILD
39 48 F 21.2 8 12.6 7.6 171.42 26 0.4 0.14 4.54 1.26 14.6 MILD
40 49 F 22.4 9.5 12.2 7.4 165.68 28 0.5 0.13 4.64 1.41 14.5 MILD
41 48 M 27.6 10 14.9 7.5 168.55 30 0.6 0.09 5.55 3.16 14.9 MOD
42 46 M 29 11 13.5 13.4 337.88 32 0.8 0.12 5.03 2.16 15.1 MOD
43 50 F 22.3 10 13.9 8 182.9 34 0.6 0.11 5.05 1.39 13.8 MILD
44 48 F 21.9 8 12.9 9.6 228.82 22 0.8 0.14 4.63 2.15 14.3 MILD
45 50 F 26.1 10 13.2 12.6 314.92 27 0.8 0.12 4.88 1.41 14.5 MILD
46 48 F 24 12 11.6 10.6 257.52 27 0.8 0.08 4.84 1.98 15.1 MOD
47 49 F 23.2 9 11.8 8.1 185.77 29 0.9 0.13 4.03 2.23 12.4 MILD
48 49 F 21.6 8 12.7 7.9 180.03 30 0.6 0.09 4.69 1.58 14.5 MOD
49 46 F 23.1 8.5 13.5 9.1 214.47 21 0.6 0.12 4.42 1.4 14.1 MILD
50 48 M 21.3 8 13.1 7.6 171.42 26 0.5 0.14 4.41 1.8 14.2 MILD
51 46 F 19.8 8 12.6 8.2 188.64 24 0.6 0.09 4.42 1.68 14.4 MILD
52 49 F 21.2 10 13.1 8 182.9 22 0.4 0.16 4.84 1.96 16.2 MOD
53 50 M 24 11 13.6 10.6 257.52 24 0.8 0.08 4.74 2.26 16.6 MOD
54 50 M 21.8 8 13.2 12.6 314.92 24 0.6 0.09 4.68 2.48 16.5 MOD
55 48 F 22.2 8 12.8 8.6 200.12 22 0.5 0.16 4.65 1.28 14.4 MILD
56 50 M 21.2 10.5 13.6 7.8 177.16 30 0.8 0.13 5.06 1.48 14.2 MILD
57 46 F 24 8 13.2 9.6 228.82 24 0.8 0.12 4.42 2.4 16.2 MOD
58 48 F 22.6 9 12.8 9.2 217.34 22 0.6 0.08 4.63 2.25 16 MOD
59 49 F 21.2 10 13.1 8 182.9 22 0.4 0.06 4.82 1.26 14.6 MILD
SL.NO Age SEX BMI D-DIABET HB HBA1C ABG UREA CREAT U.SPOT PCR RBC COUNT N/L RDW NPDR- GR
60 50 M 24 10 13.7 7.8 177.16 30 0.8 0.11 4.96 2.54 16.6 MOD
61 50 F 26.1 10 13.2 12.6 314.92 27 0.8 0.13 4.88 1.41 14.5 MILD
62 48 F 24 12 12.1 10.6 257.52 27 0.8 0.16 4.84 1.98 15.1 MOD
63 48 M 27.6 10 14.9 7.5 168.55 30 0.6 0.12 5.55 3.16 14.9 MOD
64 49 F 23.2 9 11.8 8.1 185.77 29 0.9 0.14 4.03 2.23 12.4 MILD
65 49 F 21.6 8 12.7 7.9 180.03 30 0.6 0.09 4.69 1.58 14.5 MOD
66 50 F 22.3 10 13.9 8 182.9 34 0.6 0.16 5.05 1.39 13.8 MILD
67 48 M 21.3 8 13.1 7.6 171.42 26 0.5 0.08 4.41 1.8 14.2 MILD
68 47 F 22.6 6.5 11.9 10.5 254.65 23 0.6 0.09 4.63 1.98 14.5 MOD
69 46 M 29 11 13.5 13.4 337.88 32 0.8 0.16 5.03 2.16 15.1 MOD
70 48 M 27.6 9 13.8 8.6 200.12 30 0.8 0.13 4.9 2.1 16.4 MOD
71 47 F 21.6 8 12.8 7.4 165.68 22 0.6 0.12 4.69 1.58 14.5 MILD
72 48 F 21.8 8.5 12.1 9.6 228.82 26 0.8 0.08 4.56 1.73 14.4 MILD
73 48 F 22.6 8.5 13.2 7.8 177.16 22 0.6 0.06 4.42 1.8 14.2 MILD
74 48 M 21.2 8 13.2 9.2 217.34 30 0.6 0.09 4.42 2.24 15.8 MOD
75 49 M 22 8 13.7 7.8 177.16 22 0.6 0.12 4.96 1.54 14.2 MILD
76 48 F 27.2 10 12.1 11 269 30 0.6 0.11 4.56 2.24 16 MOD
77 49 M 26 9 13.2 12 297.7 22 0.8 0.14 4.54 2.86 15.8 MOD
78 50 M 22 8 13.1 8.6 200.12 28 0.6 0.12 4.62 2.24 16.2 MOD
79 49 F 24 8.5 11.8 8.2 188.64 22 0.4 0.08 4.68 2.28 15.9 MOD
80 48 F 20.6 8 11.8 8 182.9 20 0.4 0.13 4.84 1.96 16.2 MOD
81 48 M 21 8 13.6 7.6 171.42 26 0.5 0.09 4.4 1.8 14.2 MILD
82 47 F 21.6 6.5 11.9 10.5 254.65 23 0.7 0.12 4.63 1.98 14.5 MOD
83 46 M 29 11 13.5 13.4 337.88 32 0.8 0.14 5.03 2.16 15.1 MOD
84 50 F 27.6 10 12 8 182.9 28 0.8 0.09 4.42 2.1 15.5 MOD
85 48 F 22 8 12.4 9.1 214.47 26 0.3 0.16 4.71 2.6 15.3 MOD
86 46 M 21.6 8.5 14.1 8 182.9 28 0.6 0.08 5.2 2.9 14.8 MOD
87 50 F 21.1 8 11.8 7.4 165.68 28 0.8 0.09 4.41 1.85 15.6 MILD
88 50 F 27.3 11 13.5 8.2 188.64 29 0.8 0.16 4.77 1.29 14.2 MILD
89 50 F 26.1 10 13.5 12.6 314.92 27 0.8 0.09 4.88 1.41 14.5 MILD
90 47 F 24.8 12 11.6 10.6 257.52 27 0.8 0.12 4.84 1.98 15.1 MOD
91 48 M 27.6 9 14.9 7.5 168.55 30 0.6 0.11 5.42 3.16 14.9 MOD
92 47 F 22.6 6.5 11.9 10.5 254.65 23 0.6 0.14 4.63 1.98 14.5 MOD
93 46 M 29 11 13.3 13.4 337.88 32 0.8 0.13 4.99 2.16 15.1 MOD
94 50 F 27 10 12 8 182.9 28 0.8 0.09 4.42 2.1 15.6 MOD
95 48 F 22 8 12.4 9.1 214.47 26 0.3 0.12 4.71 2.6 15.3 MOD
96 46 M 21.6 8.5 14.1 8 182.9 28 0.6 0.11 5.2 2.9 14.8 MOD
97 50 F 24 10 13.2 11 269 27 0.8 0.14 4.88 1.41 14.5 MILD
98 46 M 29 8 13.5 13 326.4 32 0.8 0.12 5.03 2.26 16 MOD
99 49 F 21.6 8 12.7 7.9 180.03 30 0.8 0.16 4.68 1.64 15.2 MOD
100 50 M 27 10 13.2 8 182.9 28 0.8 0.08 4.22 2.6 15.6 MOD
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KEY TO MASTER CHART 
  Reference Interval 
BMI Body Mass Index 18.5-24 
HB Heamoglobin M=13-18, F=11.5-16.5 
g/dL 
HBA1C Glycated Heamoglobin N=4-6%, good control= 
6-7%, Fair=7-8%, Poor 
>8% 
D-DIAB Duration of Diabetes  
ABG Average Blood Glucose N=140mg/dL 
UREA Urea 15-40 mg/Dl 
CREAT Creatinine M=0.7-1.4mg/dL, 
F=0.6-1.2 mg/dL 
U.SPOT 
PCR 
Urine Spot Protein Creatinine Ratio N=<0.2 
N/L Neutrophil : Lymphocyte Ratio N= <2 
RDW Red Cell Distribut ion Width N=11.6-14% 
RBC count Red Blood Cell Count M= 4.5-5.9, F= 3.8-5.2 
millions/ cmm 
NPDR-GR Non-Proliferative Diabetic 
Retinopathy Grade 
Mild/ Moderate 
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